PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 1  
 
Protocol Title:   A Multicenter, Open -Label, Exploratory Platform Study to Evaluate Biomarkers 
and Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration -
resistant Prostate Cancer  
Appendix Cohort A  
Protocol Number:   PI[CONTACT_150876]0033 
Amendment  Number:   Not applicable  
Compound Number:   NKTR -214, Nivolumab 
Short Title :  Platform Study for Prostate Researching Translational Endpoints Correlated to 
Response to Inform Use of Novel Combinations (PORTER)  
Sponsor Nam e and Legal Registered Address:    
Parker Institute for Cancer Immunotherapy  
[ADDRESS_415541]  
Suite D3500 
San Francisco, CA [ZIP_CODE] 
Tel: 415- 985-7311  
Fax: 415- 872-5305 
Regulatory Agency Identifying Number(s):  
IND NUMBER:  [ADDRESS_415542] NUMBER:   Not applicable  
Approval Date:   Final Pr otocol: 07 December  2018  
 Amendment 1: 24 January 2019  
 
CONFIDENTIAL  
This document and its contents are the property of and confidential to Parker Institute for Cancer 
Immunotherapy. Any unauthorized copying or use of this document is prohibited. 
  

PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 3 INVESTIGATOR PROTOCOL AGREEMENT PAGE  
I agree:  
• To assume responsibility for the proper conduct of the study at this site. 
• To conduct the study in compliance with this protocol, any future  amendments, and with 
any other study conduct procedures provided by [CONTACT_228069] . 
• Not to implement any changes to the protocol without written agreement from Par ker 
Institute for Cancer Immunotherapy  and prior review and writt en approval from the 
Institutional Review Board or Independent Ethics Committee except where necessary to 
eliminate an immediate hazard to participants . 
• That I am thoroughly familiar with the  appropriate use of the study drug(s), as described 
in this cohor t appendi x and any other information provided by [CONTACT_336389], but not limited to, the current Investigator’s Brochure(s).  
• That I am aware of,  and will comply with, the International Conference on 
Harmonisation for G ood Clinical P ractice (GCP) and all applicable regulatory 
requirements.  
• To ensure that all persons assisting me with the study are adequately informed about the 
study drugs, the Parker Institute for Cancer Immunotherapy study protocol , and of their 
study -related duties and functions as described in the protocol.  
• That I agree that persons debarred from conducting or working on clinical studies by [CONTACT_336390] d to conduct or work on studies for the 
Parker Institute for Canc er Immunotherapy or for a partnership in which the Parker 
Institute for Cancer Immunotherapy is involved, and that I will immediately  disclose in 
writing to the Parker Institute for Cancer Immunotherapy if any person who is involved in the study is debarre d, or if any proceeding for debarment is pending.  
 
 Signature:    
[CONTACT_1782]:   
 Name (print):     
 Site Number:  Principal Investigator  
 ___________   
    
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 4 Amendment(s) to Appendix Cohort A  
Text revisions resulting from the amendment(s) are incorporated in the  synopsis and body of the 
Appendix Cohort Amendment. Major changes to the appendix cohort are summarized below. 
Key Revisions in Amendment 1 ( 24 January 2019)  
Section # and Name  [CONTACT_336405]  
5.1 Inclusion Criteria  Combined previous  inclusion criteri a #6 and #10 into a single inclusion 
criterion #6.  
Study Design  
1.[ADDRESS_415543] OF FIGURES  .........................................................................................................................8  
1 PROTOCOL SUMMARY ...................................................................................................9  
1.1 SYNOPSIS  ...............................................................................................................9  
1.2 SCHEMA ...............................................................................................................10  
1.3 SCHEDULE OF ACTIVITIES ..............................................................................12  
2 INTRODUCTION  .............................................................................................................17  
2.1 STUDY RATIONALE  ..........................................................................................17  
2.2 BACKGROUND  ...................................................................................................17  
2.2.1  Background on Nivolumab (Bristol -Myers Squibb Company)  ...............18  
2.2.2  Background on NKTR -214 (Nektar Therapeutics)  .................................18  
2.2.3  Rationale for NKRT -214 + Nivolumab Immunotherapy Combination ..20 
2.3 BENEFIT/RISK ASSESSMENT  ..........................................................................24  
3 OBJECTIVES AND ENDPOINTS  ...................................................................................25  
4 STU DY DESIGN ...............................................................................................................26  
4.1 OVERALL DESIGN  .............................................................................................26  
4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN ...........................................27  
4.3 JUSTIF ICATION FOR DOSE  ..............................................................................27  
4.3.1  Rationale for Nivolumab Dose and Schedule  .........................................27  
[IP_ADDRESS]  Nivolumab 360 mg Q3W Dosing Regimen  ..........................28  
4.3.2  Rationale for NKTR -214 Dose and Schedule  .........................................28  
4.4 TREATMENT BEYOND DISEASE PROGRESSION  ........................................29  
4.5 END OF STUDY DEFINITION  ...........................................................................29  
5 STUDY POPULATION  ....................................................................................................29  
5.1 INCLUSION CRITERIA .......................................................................................29  
5.1.1  Common Inclusion Criteria  .....................................................................29  
5.1.2  Combination- specific Inclusion Criteria  .................................................32  
5.2 EXCLUSION CRITERIA .....................................................................................32  
5.2.1  Common Exclusion Criteria  ....................................................................32  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 6 5.2.2  Combination- specific Exclusion Criteria  ................................................33  
5.3 LIFESTYLE CONSIDERATIONS  .......................................................................34  
5.3.1  Meals and Dietary Restrictions  ...............................................................34  
5.3.2  Activity  ....................................................................................................34  
5.4 SCREEN FAILURES  ............................................................................................34  
6 STUDY INTERVENTION ................................................................................................34  
6.1 STUDY INTERVENTION(S) ADMIN ISTERED  ................................................34  
6.1.1  Hydration Guidelines for NKTR -214 ......................................................35  
6.2 PREPARATION/HANDLING/STOR AGE/ACCOUNTABILITY  ......................36  
6.3 RANDOMIZATION AND BLINDING ................................................................36  
6.4 STUDY INTERVENTION COMPLIANCE  .........................................................36  
6.5 CONCOMITANT THERAPY...............................................................................36  
6.5.1  Permitted Therapy  ...................................................................................36  
6.5.2  Prohibited Therapy  ..................................................................................36  
6.6 DOSE MODIFICATIONs  .....................................................................................36  
6.6.1  Dose Modifications for the Combination of Nivolumab and NKTR -214
 .................................................................................................................36  
[IP_ADDRESS]  Potential for Overlappi[INVESTIGATOR_336368] -214 .............................................................................38  
[IP_ADDRESS]  Dose Modifications and T oxicity Management for Adverse 
Events Associated with Nivolumab a nd NKTR -214 .............39  
[IP_ADDRESS]  Dose Modifications and Toxicity Management for Infusion-related Reactions Associated with the Administration of NKTR -214 and/or Nivolumab ...............................................40
 
[IP_ADDRESS]  Dose Delays and Interruptions of NKTR -214 + Nivolumab 
Combination Immunotherapy  ................................................42  
6.6.2  Dose Modifications f or Nivolumab .........................................................42  
6.6.3  Dose Modifications for NKTR -214 .........................................................44  
[IP_ADDRESS]  Permanent Treatment Discontinuation Criteria  .....................46  
7 DISCONTINUATIONS OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL ..........................................................................48
 
7.1 DISCONTINUATION OF STUDY INTERVENTION  ........................................48  
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM STUD Y ........[ADDRESS_415544] TO FOLLOW -UP .......................................................................................48  
8 STUDY ASSESSMENTS AND PROCEDUR ES .............................................................48  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 7 8.1 EFFICACY ASSESSMENTS  ...............................................................................48  
8.1.1  Laboratory Assessments  of Clinical Activity  ..........................................48  
8.2 SAFETY ASSESSMENTS  ....................................................................................49  
8.2.1  Increased Monitoring and Vital Sign Guidelines for Infusion- related 
Reaction or Hypotension  .........................................................................49  
8.2.2  Echocardiograms  .....................................................................................49  
8.2.3  Clinical Safety Laborato ry Assessments  .................................................49  
[IP_ADDRESS]  Local Laboratory Assessments  ..............................................[ADDRESS_415545]  ..........................................................51  
8.4 TREATMENT OF OVERDOSE  ...........................................................................51  
8.5 PHARMAC OKINETICS  .......................................................................................51  
8.6 ANTI -DRUG ANTIBODIES  ................................................................................51  
8.7 BIOMARKERS  .....................................................................................................51  
8.8 MEDICAL RESOURCE UTILIZATION AND HEALTH ECONOMICS  ..........51  
9 STATISTICAL CONSIDERATIONS ...............................................................................51  
9.5.1  Interim Safety Monitoring  .......................................................................51  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ....52  
10.1  APPENDIX A- 1: MANAGEMENT ALGORITHMS  ..........................................53  
10.2  APPENDI X A- 2: LISTS OF TERMINOLOGY AND ABBREVIATIONS  ........[ADDRESS_415546] of Abbreviations  ...............................................................................61  
10.3  APPENDIX A- 3: APPENDIX COHORT A AMENDMENT HISTORY  ............[ADDRESS_415547] OF TABLES  
Table 1:  Schedule of Activities  ............................................................................................13  
Table 2:  Overall Tumor Response by [CONTACT_334258]: PI[INVESTIGATOR_12964] -02 Dose -escalation Ph ase .....21  
Table 3:  Overall Tumor Response by [CONTACT_334258]: PI[INVESTIGATOR_12964] -02 Expansion at 
Recommended Phase 2 Dose  .................................................................................22  
Table 4:  Safety: PI[INVESTIGATOR_12964] -02 Expansion at Recommended Phase 2 Dose  .............................23  
Table 5:  Cohort -Speci fic Objectives and Corresponding Endpoints  ...................................26  
Table 6:  Study In tervention  ..................................................................................................34  
Table 7:  Toxicity Criteria Requiring Permanent Treatment Discontinuation  ......................38  
Table 8:  Dose Modification and Toxici ty Management Guidelines for Infusion- related 
Reactions Associated with the administration of NKTR -214 and/or Nivolumab .41 
Table 9:  Dose Modification and Toxicity Management Guidelines for Adv erse Events 
Associated with Nivolumab  ...................................................................................43  
Table 10:  Laboratory Tests Sent to the Study Site’s Local Laboratory for Analysis of 
Disease- related Endpoints  ......................................................................................49  
Table 11:  Laboratory Tests Sent to the Study Site’s Local Laboratory for Analysis of Safety................................................................................................................................[ADDRESS_415548] OF FIGURES  
Figure 1:  Study Schema .........................................................................................................11  
  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 9 1 PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Protocol Title:  
A Multicenter, Open -Label, Exploratory Platform Study to Evaluate Biomarkers and 
Immunotherapy Combinations for the Treatment of Patients with Metastatic Castration -resistant 
Prostate Cancer  
Appendix Cohort A  
Short Title:  
Platform Study for Prostate Researching Translational Endpoints Correlated to Response to 
Inform Use of Novel Combinations (PORTER)  
Note to Investigators :  This cohort  appendix is intended to supplement the core protocol , and as 
such, will focus on combination- specific ( ie, NKTR -214 and nivolumab) information that is not 
already available in the core protocol.  
Rationale : 
This study cohort is designed to explore  the immu ne activation  properties of NKTR -214 by  
[CONTACT_336391] T and natural killer (NK) lymphocytes when used in combination 
with anti -programmed cell death 1 ( PD-1) therapy  in metastatic castration -resistant prostate 
cancer (mCRPC) . 
Objectives and Endpoints : 
Refer to the core protocol . 
Com bination- specific exploratory objectives include:  
Combination -specific Exploratory Objectives  Endpoints  
• To evaluate the PK of NKTR -214 and/or nivolumab.  
• To evaluate the immunogenicity (ADA) of 
NKTR -214 and/or  nivolumab.  • Sparse PK analysis  
• Presence of ADA against NKTR -214 and/or  
nivolumab.  
ADA = anti -drug antibodies; PK = pharmacokinetics  
 
Overall Design, Number of Participants, Follow -up, and Data Monitoring Committee:  
Refer to the c ore protocol . 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 10 Intervention  Groups and Duration:  
Participants will be assigned to receive one of the enrolling immunotherapy combination study 
interventions. In this cohort, participants will receive NKTR -214 and nivolumab as follows:  
Intervention  Dose Frequency  Route  Schedule  
NKTR -214 0.006 mg/kg  Q3W IV over 30 (± 5) minutes  Starting Day 1  
Nivolumab  360 mg  Q3W IV over 30 minutes  Starting Day 1  
IV = intravenous(ly); Q3W = every 3 weeks  
 
Participants will be administered intravenous ( IV) fluid and provided guidelines for self -
administered oral hydration following administration  of NKTR -214. 
NKTR -214 and nivolumab will be administered for up to 2 years, unless the participant : is no 
longer clinically benefiting (as evidenced by [CONTACT_336392]/or clinical deterioration ); experiences any toxicit y meeting specifi ed discontinuation criteria 
(see Section  6.6) or unacceptable toxicity  in the best clinical discretion of the treating physician  
(ie, Investigator discretion); reaches the maximum duration  of st udy intervention; or  withdraws 
consent . In this cohort, a cycle is defined as 3 calendar weeks.  
1.2 SCHEMA 
The study schema is depi[INVESTIGATOR_90850] 1.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 11 Figure 1 : Study Schema  
 
IV = intravenously ; mCRPC = metastatic castration -resistant prostate cancer; Q3W = every 3 weeks; S  = screening  
NKTR -214 and nivolumab will be administered for up to 2  years, unless the participant: is no longer clinically benefiting (as evidenced by [CONTACT_336393]/or clinical deterioration); experiences any toxicity meeting specified discon tinuation criteria ( see Section 6.6 ) or 
unacceptable toxicity  in the best clinical discretion of the trea ting physician; reaches the maximum duration of study intervention; or withdraws consent. A cycle 
is defined as 3 calendar weeks. Participants will be followed for up to  2.5 years from the time of the initiation o f study intervention.  
This study design is applicable to Stage 1, as well as Stage 2 if the cohort is expanded.  

PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix  Amendment 1, Version 2.0 12  
1.3 SCHEDULE OF ACTIVITIES  
The Schedule of Activities (SOA) shown in Table  1 is specific for this combination and 
supersedes the SOA provided in the core protocol . 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 13 Table  1: Schedule of Activities  
Tests & Procedures  Screening/ 
Enrollmenta On-Treatment: NKTR -214 + Nivolumab  End of 
Treatmentb Follow -up Cycle 1 (Q3W)  Cycles 2, 3, and [ADDRESS_415549] 
Day Day -28 to 
Day -1 Day 1  Day 2 Day 3  Day 8  Day 1  Day 8  Day 1  Day 
8 14 – [ADDRESS_415550] 
dose Q3Mc 
Window (days)  -28  ± 1 ± 1 ± 1 ± 3 ± 1 ± 3 ± 3 ± 7 ± 10 ± 14 
Informed consentd X            
Review of I/E criteria  X            
Medical/cancer history  X            
Physical examination  X X    X  X  X   
ECOG performance 
status  X X    X  X  X X  
Vital signs ( see Core 
Protocol Section 8.2.3 ) X X    X  X  X   
Body weight  X X    X  X  X   
Hematology  (see Table 
11) X Xe X X X Xe X Xe X X X  
Clinical chemistry  (see 
Table 11) X Xe   X Xe X Xe X X X  
Urinalysis  X X    X  X  X   
Prostate -specific antigen  X X    X  X  X X  
Testosterone level  X            
12-lead ECG  X X X X X X  X     
ECHO/MUGA  X         X X  
Circulating tumor cellsf  Xe    Xe  Xe  X   
cfDNA (blood)g X     Xe (Cycles 
2 and 4)     X   
Circulating soluble 
analytes/PK/ADAh X Xe X  X Xe (Cycles 
2, 3, and 4)     X   
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 14 Tests & Procedures  Screening/ 
Enrollmenta On-Treatment: NKTR -214 + Nivolumab  End of 
Treatmentb Follow -up Cycle 1 (Q3W)  Cycles 2, 3, and [ADDRESS_415551] 
Day Day -28 to 
Day -1 Day 1  Day 2 Day 3  Day 8  Day 1  Day 8  Day 1  Day 
8 14 – [ADDRESS_415552] 
dose Q3Mc 
Window (days)  -28  ± 1 ± 1 ± 1 ± 3 ± 1 ± 3 ± 3 ± 7 ± 10 ± 14 
NKTR -214 PKi X Xe X  X Xe (Cycles 
2, 3, and 4)     X   
Blood immune 
biomarkersh X Xe   X Xe 
(Cycles  2, 
3, and 4)     X   
Archival tumor tissue  X            
Tumor biopsyj X     X 
(Cycle  2)  
  X (at PD  
[optional] )j   
Stool collectionk X     X 
(Cycle  2)k       
Concomitant 
medicat ions X X X X X X X X X X X  
Adverse events  All AEs and SAEs will be collected for at least [ADDRESS_415553] dose of study  intervention.l  
NKTR -214 
administrationm  X    X  X     
Administer IV fluidsn  X    X  X     
Nivolumab 
administrationo  X    X  X     
Radiographic d isease 
assessment  X At Week 9 ( ± 1 week) , repeat every 9 weeks ( ± 1 week)  for the first 27 weeks,  and every 12 weeks ( ± 1 week)  
thereafter until radiographic PD or start of subsequent therapy  
Review  of alternate 
anticancer therap yp           X X 
Follow up for overall 
survival            X X 
ADA = anti -drug antibodies; AE(s) = adverse event (s); cfDNA  = cell -free deoxyribonucleic acid; ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern 
Cooperative Oncology Group; EOT  = end of treatment; I/E  =  inclusion/exclusion; IV = intravenously; MUGA = multigated acquisition; PD = progressive disease; 
PK = pharmacokinetics; Q3M = every 3 months ; Q3W  = every 3 weeks ; SAE(s) = serious adverse event (s) 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 15 a Tests/procedures performed as s tandard of care prior to obtaining informed consent and within [ADDRESS_415554] be obtained prior to any study -specific procedures and may be obtained prior to the 28-day screening window.  
e Blood samples should be  collected prior to administration of any study intervention . 
f Circulating tumor cells will be collected  at baseline (ie, Day 1 of Cycle 1 prior to study intervention administration), Day 1 of each cycle  (prior to study intervention 
administration) , and EOT.  
g cfDNA (blood) will be collected  at baseline (ie, screening  visit prior to study intervention administration), Day 1 of Cycle 2 and Cyc le 4, and EOT.  
h Circulating soluble analytes, PK (nivolumab) and ADA blood sample, and /or blood immune biomarkers will be collected  at baseline (ie, screening and/or Day 1 of Cycl e 1 prior 
to study intervention administration),  Day 2 of Cycle 1 (circulati ng soluble analytes) , Day 8 of Cycle 1 (circulating soluble analytes , and blood immune biomarkers), prior to 
study intervention administration on  Day [ADDRESS_415555] -infusion of NKTR -214 (prior 
to nivolumab administration) on Day 1  of Cycles 1 -4. Additionally, PK blood samples w ill be collected on Day 2 and Day 8 of Cycle 1.  
j Participants will undergo 2 -3 tumor biopsies: prior to beginning study intervention  (ie, baseline biopsy, mandatory for all participants, including those with bone only  disease if 
medically feasible), and d uring treatment (ie, on -treatment biopsy during Cycle 2, if medically feasible). On - treatment biopsy should occur as early as possible a fter the second 
dose (Day 2 –  Day 10 of Cycle 2); however, any on treatment biopsy after Day 1 of Cycle 2 will be accep ted. An optional biopsy may be obtained at the time of disease 
progression, including from participants who respond and subsequently prog ress. Every attempt should be made for the on-treatment biopsies to be taken from the same lesion as 
the pre -treatment biopsy when feasible.  
k Stool will be collected at screening and during Cycle 2, if possible. Otherwise, any  on-treatment stool sample wi ll be acceptable.  The s tool sample may be collected at the clinic 
or at the participant’s home.  
l All SAEs will be collected from the time the participant signs informed consent. Prior to initiation of study intervention, only SAEs that are rel ated to a pr otocol -mandated 
intervention, including those that occur prior to the assignment of study procedures should be reported. All AEs will be collected from the start of study intervention. All AEs 
and SAEs will be collected for at least  [ADDRESS_415556] dose of study intervention. Refer to Section 8.3 of the core protocol  for details regarding safety reporting for this 
study.  
m NKTR -214 will be administered at a dose of 0.006 mg/kg IV over 30 minutes Q3W on the same day as nivolumab and will continue for u p to 2  years, unless the participant : is 
no longer clinically benefiting  (as evidenced by [CONTACT_336394]/or clinical deterioration) ; experiences any toxicity meeting specified 
discontinuation criteria  (see Section 6.6) or unacceptable toxicity in  the best clinical discretion of the treating physician ; reaches the maximum duration of study intervention ; or 
withdraws consent.  A cycle is defined as [ADDRESS_415557] 1 liter of IV fluid will be administered  prior to NKTR -214 administration  on the day of each NKTR -214 dose . For the next 3 days after administration (ie, Days 2 -4 of 
each cycle), participants are required to drink at least 2 liters per day of self -administered oral hydration  (note: alcohol and caffeine intake should not be count ed toward the daily 
hydration requirements) . Advise participants to restrain from strenuous activity and avoid long ho t showers and saunas for Days [ADDRESS_415558] of the participant  (eg, 
evidence of fluid overload) . Advise participants with orthostatic symptoms to call their treating oncologist and consider increasing  oral hydration (s ee Section 6.1.1 ). 
o Nivolumab will be administered at a dose of 360 mg IV over 30 minutes Q3W and will continue for up to 2 years, unless the participant: is no longer clinically benefiting (a s 
evidenced by [CONTACT_336394]/or clinical deterioration); experiences any toxicity meeting  specified discontinuation criteria (see Section 6.6) 
or unacceptable toxicity in th e best clinical discretion of the treating physician; reaches the maximum duration of study intervention ; or withdraws consent.  A cy cle is defined as 
[ADDRESS_415559] -study intervention alternate anticancer therapy.  
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 17 2 INTRODUCTION 
Refer to the core protocol . 
2.1 STUDY RATIONALE  
Refer to the core protocol . 
2.2 BACKGROUND  
Immunotherapy has changed the landscape of treatments for a number of malignancies,  resulting 
in marked clinical benefit for patients with cancers including metastatic melanoma, non- small 
cell lung cancer ( NSCLC ) and renal cell carcinoma ( RCC) . Studies of immunotherapy in patients 
with advanced prostate cancer have failed to yield similar results. A phase 3 randomized, 
controlled trial of ipi[INVESTIGATOR_336369]- resistant 
prostate cancer (mCRPC) failed to  meet its primary endpoint of overall survival ( OS; Kwon et 
al., 2014), and early phase studies of programmed cell death 1 ( PD-1) blockade in advanced 
malignancies did not demonstrate clinical activity in advanced prostate  cancer ( Topalian et al., 
2012). However, emerging dat a suggest subsets of patients with prostate cancer, such as those 
with microsatellite instable tumors, which are enriched for neoantigens for T cells to respond to, 
may respond to anti -PD-1 immunotherapy ( Graff et al., 20 16). 
The prostate has historically been thought to be an immune -privileged site, with disease evidence 
of intratumoral natural killer ( NK) cells, macrophages, and ‘ low levels’ of both CD4+ and CD8+ 
T cells in prostate tumor tissue (Flammiger et al., 2012; Sfanos et al, 2009; De Marzo et al., 2007; Massari et al., 2016 ). As a ‘cold’ tumor, the immunosuppres sive microenvironment may 
contribute to the lack of clinical benefit to immunotherapy in prostate cancer, including low 
programmed cell death ligand 1 ( PD-L1) expression  (Martin et al., 2015), low mutational burden 
(Alexandrov et al., 2013), low abundance of intratumoral T cells ( Flammiger et al., 2012), low 
cytolytic activity of NK cells ( Pasero et al., 2 016), and accumulation of regulatory T cells 
(Tregs) and myeloid -derived suppressor cells (MDSCs) in tumor bed ( Miller et al., 2006; Lopez -
Bujanda and Drake, 2017 ). Treatment -based approaches that address these mechanisms of 
immune evasion or identify immune -responsive patient subsets may a llow for more successful 
immunotherapy treatment approaches for this patient population with high unmet medical need.  
The T cell cytokine interleukin 2 (IL -2) is a potent antitumor cytokine, with a long clinical 
history as one of the first immunotherapeut ic agents for the treatment of cancer. Aldesleukin 
(Proleukin®), which is approved by [CONTACT_24623] (US) Food and Drug Administration (FDA) for metastatic melanoma and metastatic renal cell carcinoma, directly stimulates the 
immune system and has been shown to lead to durable responses in ~10% of people with metastatic melanoma and renal cancer ( Payne et  al., 2014). However, in addition to acting as a 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 18 stimulator of the immune system by [CONTACT_336395]8+ T c ells, aldesleukin also 
suppresses the immune system by [CONTACT_336396] ( Boyman and Sprent, 2012).   
Despi[INVESTIGATOR_336370], it has several therapeutic 
limitations, including th e need for inpatient hospi[INVESTIGATOR_98166], [ADDRESS_415560] long lasting durable responses, including patients considered non -responders with stable 
disease (SD) ( McDermott et al., 2015 ). These data underscore the relevance of cytokines and the 
need for improved cytokine therapi[INVESTIGATOR_336371].  
2.2.1 Background on Nivolumab (Bristol-Myers Squibb Company)  
Nivolumab is a human immunoglobulin G4 (IgG4) m onoclonal antibody that binds to the PD -[ADDRESS_415561] -mediated 
inhibition of the immune response, including the antitumor immune response. Opdivo® 
(nivolumab) is approved in the US for the treatment of several cancer types, including 
unresectable or metastatic melanoma (as monotherapy or in combination with ipi[INVESTIGATOR_125]) an d 
as monotherapy in previously -treated metastatic NSCLC, advanced RCC, relapsed or refractory 
classical Hodgkin lymphoma  (cHL), locally advanced or metastatic urothelial carcinoma (UC); 
recurrent or metastatic squamous cell carcinoma of the head and neck ( SCCHN), microsatellite 
instability -high (MSI -H) or mismatch repair deficient (dMMR) metastatic colorectal cancer 
(CRC), and hepatocellular carcinoma (HCC). In phase 1 investigation, nivolumab did not 
demonstrate clinical activity in 17 participants with mC RPC.  This is consistent with mCRPC 
having a low level of immune cell infiltrate and tumor mutational burden (TMB). Treat ment 
strategies to increase antigen presentation and immune infiltration  and activation  may improve 
the immune responsiveness of mCRPC t o nivolumab. 
Refer to the Investigator’s Brochure ( IB; Nivolumab Investigator ’s Brochure, 2018)  and 
approved US prescribing information ( Opdivo [nivolumab] US Prescribing Information [ USPI ], 
2018) for detailed background information on nivolumab. 
2.2.2 Background on  NKTR -214 (Nektar Therapeutics)  
NKTR -214 is a novel cytokine with enhanced immune system activation. NKTR -214 consists of 
IL-2, which has the same amino acid sequence as aldesleukin (recombinant human IL -2 [rhIL -
2]), conjugated at a defined region within the protein to releasable polyethylene g lycol (PEG) 
chains. In contrast to high- dose aldesleukin, which requires patients to be hospi[INVESTIGATOR_336372], NKTR -214 was desi gned as an outpatient therapy. In addition, NKTR -214 was 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 19 designed to mitigate the serious toxicities associated with r apid systemic immune activation seen 
with administration of high -dose IL -2 (NKTR -214 Investigator’s Brochure, 2018).  
NKTR -214 is a prodrug of a conjugated cancer immunotherapy cytokine that exerts its biological 
activity by [CONTACT_336397] -2 receptor and subsequent activation of effector T cells. The PEG 
chains of NKTR -214 render the molecule inactive. U pon intravenous (IV) administration, the 
PEG chains slowly release via hydrolysis to generate the active cytokine speci es (2 -PEG -IL-2 
and 1- PEG -IL-2) that have a peak plasma concentration 26 to 30 hours after infusion. The slow 
generation of the 2 -PEG -IL-2 and 1 PEG -IL-2 significantly mitigates the rapid -onset, systemic 
cytokine -related toxicities associated with high dose  IL-2. Furthermore, the prodrug design of 
NKTR -214 with its antibody -like dosing, and the long half -life (13 to 19 hours) and sustained 
CD122 signaling of the active NKTR -214 moiety, obviate the need for 5- day courses of thrice 
daily infusions, or of daily  subcutaneous injections. 
The polymer conjugation of NKTR -214 promotes biased signaling through the IL -2 receptor beta 
gamma (IL -2Rβγ). T his unique feature preferentially increases the proliferation, activation and 
effector function of tumor antigen- specif ic CD8+ T cells and NK cells within the tumor 
microenvironment without expanding unwanted intra -tumoral Tregs that are activated through 
the IL -2 receptor alpha beta gamma (IL -2Rαβγ) ( Charych et al., 2016a ; Charych et al., 2016b). 
Specifically, the location of the NKTR -[ADDRESS_415562] of activating Tregs in the tumor while continuing to permit 
binding to the IL -2Rβγ (CD122) receptor.  
NKTR -214 also correspondingly promotes expression of PD -1 on the surface of CD8+ T cells 
and induction of a  Type II interferon gene signature [CONTACT_336406], driving cell 
surface expression of PD -L1 on tumor cells ( Diab et al., 2017a ). The immunogenic properties of 
NKTR -214 with the induction of tumor infiltrat ing lymphocytes and upregulation of the 
PD-1/PD -L1 axis makes NKTR -214 a potentially promising combination therap y for use with 
checkpoint inhibitors that target and inhibit the PD -1/PD -L1 pathway.  
Multiple phase 1/[ADDRESS_415563] in which NKTR -214 is administered 
either  as monotherapy or  in combination with immune checkpoint inhibitors, such as nivolumab, 
once every 2 or 3 weeks for the treatment of solid tumors ( Charych et al., 2017). NKTR -214 has 
been generally well -tolerated in the clinical studies to date, with promising evidence of clinical 
efficacy  in cancer patients,  indicating a favorable benefit -risk profile. While no objective 
responses were observed in the s ingle -agent study of NKTR -214 ( Study 15- 214-01 [EXCE L]), 9 
patients experienced tumor shrinkage between 1% and 30% , and 2 patients, after progressing on 
multiple prior therapi[INVESTIGATOR_014], had durable SD > [ADDRESS_415564] of the cytokines released in 
response to NKTR -214. Other common adverse events ( AEs) associated with NKTR -214 appear 
to be largely cytokine -driven, are generally mild or mode rate in severity and self -limiting.  
Refer to the IB (NKTR -214 Investigator ’s Brochure, 2018 and Addendum  1 to NKTR -214 
Investigator’s Brochure , 2018)  for detailed  background information on NKTR -214. 
2.2.3 Rationale for NKRT -214 + Nivolumab Immunotherapy 
Combination  
Given the safety profile, modest antitumor activity , and observed pharmacodynamic effects of 
NKTR -214 on increasi ng PD -L1 expression and induction of interferon gene signature [INVESTIGATOR_1238] T and 
NK lymphocytes in the tumor, a major focus of the development of NKTR -214 treatment is in 
combination with PD -1 checkpoint  inhibitors. In an ongoing phase 1/2 study of NKTR -214 and 
nivolumab in immuno -oncology naive patients with locally advanced or metastatic solid tumor 
malignancies ( Study 16 -214-02 [PI[INVESTIGATOR_12964] -02 study] ), a total of 38 patients  with melanoma, 
NSCLC, RCC were enrolled in the phase 1b dose -escalation  cohort . Among these patients , 
clinical activity was observed in both PD -L1 negative and positive patient s (Table 2) . The 
recommended phase 2 dose for the combination is 0.006 mg/kg NKTR -214 and 360 mg 
nivolumab administered on the same day every 3 weeks  (Q3W).  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 21 Table 2:  Overall Tumor Response by [CONTACT_334258]: PI[INVESTIGATOR_12964] -02 Dose -escalation Phase  
 Melanoma 
(1L) 
(N = 11)  RCC (1L)  
(N = 14 ) NSCLC (2L)  
(N = 4 ) NSCLC 
(1/2L)  
(N = 5)  
Best Overal l Response (RECIST)      
ORR (CR + PR)    7 (64%)  10 (71%)  3 (75%)  3 (60%)  
DCR (CR + PR + SD)  10 (91%)  11 (79%)  3 (75%)  4 (80%)  
ORR by [CONTACT_4002]-L1 Status      
PD-L1 (-) 3/5 (60%)  5/8 (63%)  3/4 (75%)  3/5 (60%)  
PD-L1 (+)  4/6 (67%)  4/5 (80%)  0 0 
PD-L1 Unknown  0 1/1 0 0 
Source: Diab et al., 2018  
1L = first -line; 2L = second -line; CR = complete response; DCR = disease control rate; NSCLC = non -small cell 
lung cancer; ORR  = objective response rate; PD -L1 = programmed cell death li gand -1; PR = partial response; 
Q3W  = every 3 weeks; RCC  = renal cell carcinoma; RECIST  = Response Evaluation Criteria in Solid Tumors ; 
SD = stable disease  
Data included for the following d oses studied:  NKTR- 214 0.006 mg/kg Q3W + nivoloumab 240 mg QW; NKTR -
214 0.003 mg/kg Q2W + nivolumab 240 mg Q2W; 0.006 mg/kg Q2W + nivolum ab 240 mg Q2W; 0.006 mg/kg 
Q3W + nivolumab 360 mg Q3W  
Data cut: [ADDRESS_415565] cancer (TNBC) have been  treated at the recommended phase [ADDRESS_415566] -
line (1L) patients from the dose -escalation cohort (7 melanoma and 11 RCC ; Diab et al., 2018).  
Three of the phase 2 expansion cohorts ha ve met the pres pecified efficacy criteria  as of the 29 
May 2018 data cutof f, sup porting the evaluation of NKTR -214 and nivolumab in registrational 
trials ( Table 3).  Enrollment is ongoing  for additional tumor types in immuno -oncol ogy naive  and 
refractory settings.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 22 Table 3:  Overall Tumor Response by [CONTACT_334258]: PI[INVESTIGATOR_12964] -02 Expansion at 
Recom mended Phase 2 Dose  
 Melanoma Stage IV 
Naive 1L  
(N = 28)  RCC Stage IV 
Naive 1L  
(N = 26)  UC Stage IV  
Naive 1L  
(Cisplatin -
ineligible)  
(N = 10)  
Best Overall Response (RECIST)     
ORR (CR + PR)  14 (50%)  12 (46%)  6 (60%) 
DCR (CR + PR + SD)  20 (71%)  20 (77%)  7 (70%) 
ORR by [CONTACT_4002]-L1 Status     
PD-L1 (-) 5/12 (42%)  9/17 (53%)  3/5 (60%) 
PD-L1 (+)  8/13 (62%)  2/7   (29%)  3/5 (60%)  
PD-L1 Unknown  1/3   (33%)  1/5   (50%)  0 
Source: Diab et al., 2018  
CR = complete response; DCR = disease control rate; 1L = first -line; ORR  = objective response rate; 
PD-L1 = programmed cell death ligand -1; PR = partial resp onse; RCC  = renal cell carcinoma; RECIST  = Response 
Evaluation Criteria in Solid Tumors ; SD = stable disease ; UC = urothelial carcinoma  
Recommended phase 2 dose : NKTR -214 0.006 mg/kg in combination with nivolumab 360 mg every 3 w eeks 
Data cut: 29 May 2018  
 
The combination i s safe and well -tolerated  at the recommended phase 2 dose , with a low rate of 
≥ Grade 3 treatment -related AEs, including immune -mediated AEs  (imAEs; Tabl e 4). 
Cytokine -related toxicity is the most common toxicity observed in patients treated with 
NKTR -214 in combination with nivolumab. These  toxicities, reported either as stand -alone 
clinical dia gnoses or as the associated individual signs and symptoms, including flu- like 
symptoms, rash, pruritus, cytokine release syndrome, fatigue, and elevated hepatic 
transaminases , are generally mild or mo derate in severity  and are generally self-limitin g. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 23 Tabl e 4: Safety : PI[INVESTIGATOR_12964] -02 Expansion at Recommended Phase 2 Dose  
Preferred Term  NKTR -214 0.006 mg/kg  + 
Nivo 360  Q3W 
(N=283)  
Treatment -Related  AE Grade 1 -2 in >  15%   
Flu-like sympt omsa 166 (58.7%)  
Rashb 126 (44.5%)  
Fatigue  119 (42.0%)  
Pruritus  89 (31.4%)  
Nausea  62 (21.9%)  
Decreased appetite  54 (19.1%)  
Diarrhea 43 (15.2%)  
Treatment -Related AE Grade 3 or higher (≥  1% listed below)  40 (14.1%)  
Hypotension 5 (1.8%)  
Syncope  5 (1.8%) 
Increased lipase  4 (1.4%)  
Rashb 4 (1.4%)  
Dehydration  3 (1.1%)  
Patients who discontinued due to a TRAE  6 (2.1%)  
Any Immune -Mediated AE (≥ Grade  3) 10 (3.5%)  
≥ Grade 3 Immune -Mediated AE Treated with Steroid / 
Immunomodulating Medication 7 (2.5%)  
Pneumonitisc/dyspnea  2 (0.7%)  
Skin adverse event  2 (0.7%)  
Hepatitis  1 (0.4%)  
Colitis  1 (0.4%)  
Elevated lipase  1 (0.4%)  
≥ Grade 3 Endocrinopathy  3 (1.1%)  
Diabetes mellitus treated with i nsulin  1 (0.4%)  
Hyperglycemia treated with insulin  2 (0.7%)  
Source: Diab et al., 2018  
AE(s) = adverse event(s); MedDRA = Medical Dictionary for Regulatory Activities ; Q3W = every 3 week s; 
TRA E(s) = treatment -related adverse event (s) 
Data cut: [ADDRESS_415567] grade  
a Flu-like symptoms includes the following MedDRA preferred terms: c hills; influenza ; influenza -like illness ; 
pyrexia.  
b Rash includes the following MedDRA preferred terms: r ash; rash erythematous ; rash maculo-papular ; rash 
pruritic ; erythema ; rash generalized ; rash popular;  rash pustular ; rash macula r 
c One treatment -related G rade 5  pneumonitis related to nivolumab in a patient with NSCLC pretreated with 
carboplatin/pemetrexed and history of brain metastases  
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 24 Translational data from the PI[INVESTIGATOR_12964] -02 study confirm the rationale for activation of the immune 
system in the tumor microenviron ment , with a conversion of PD -L1 negative tumors to PD -L1 
positive on treatment  in 9/17 (53%) of patients  (Diab et al., 2018) . 
Given that NKTR -214 administration results in increasing PD -L1 expression and induction of 
interferon gene signature [INVESTIGATOR_1238] T and NK lymphocytes in the tumor, it may overcome some of the 
immune evasion mechanisms identified in  mCRPC. NKTR -214 is a potentially promising 
immune -activating agent in combination therapy with checkpoint inhibitors targeting the 
PD-1/PD -L1 pathway , such as nivolumab. Moreover, the side effect profile of NKTR -214 does 
not overlap with that of checkpoint inhibitors, further supporting the use of NKTR -214 as a 
potentially complimentary combination partner with nivolumab. 
2.3 BENEFIT/RISK ASSESSMENT 
Nivolumab  
Nivolumab has demonstrated durable responses exceeding [ADDRESS_415568] AEs were low -grade 
(Grade 1 to 2) with relatively few related high -grade (Grade 3 to 4) AEs. There is no pattern in 
the incidence, severity, or causality of AEs to nivolumab dose level. Clinica lly-relevant AEs 
typi[INVESTIGATOR_228032]  
(Nivolumab Investigat or’s Brochure, 2018).   
In several ongoing clinical trials, the safety of nivolumab in combination with other therapeutics such as ipi[INVESTIGATOR_125], cytotoxic chemotherapy, anti -angiogenics, and targeted therapi[INVESTIGATOR_33217] b eing 
explored. Most studies are ongoing and, as such, the safety profile of nivolumab combinations continues to evolve.  
Overall, these findings support a favorable benefit -risk profile for nivolumab across various 
tumor types. More detailed information about the known and expected benefits and risks and reasonably expected AEs of nivolumab may be found in the prescribing information  (Opdivo 
USPI, 2018).  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 25 NKTR -214 
NKTR -214 has been generally well -tolerated in the clinical studies to date, both as monotherapy 
as well as in combination with immune checkpoint inhibitors, such as nivolumab, with promising 
evidence of clinical efficacy indicating a favorable benefit -risk profile  (NKTR -214 Inves tigator’s 
Brochure, 2018) . NKTR -[ADDRESS_415569] clinically important risk, hypotension, can be effectively mitigated by [CONTACT_336398]. Other common AEs associated with NKTR -214 appear to be largely 
cytokine -driven, are generally mild or moderate in severity and self -limiting. Importantly, 
although cases of hypothyroidism, thyroiditis, and vitiligo/hypopi[INVESTIGATOR_336373] -mediated mechanism have been observed in participant s receiving NKTR -[ADDRESS_415570] 
participants  from clinically significant toxicities.  
NKTR -214 and Nivolumab  
The safety profile of nivolumab is well characterized and manageable when administered  alone 
or in combination, including regim ens where it is administered in combination with additional 
immuno -oncology products. The risk of hypotension with NKTR -214 seen in the monotherapy 
study was mitigated by [CONTACT_336399] a hydration protocol in the PI[INVESTIGATOR_12964] -02 study and 
these guidelines  will be used in the current study. The current aggregate safety data for patients 
treated with the combination appears similar to nivolumab monotherapy. Nonclinical data , as 
well as clinical experience with high do se IL -2 and checkpoint inhibitor combinat ions, indicate 
the potential for improvement in therapeutic response compared with either agent given alone. Thus, the potential benefit of this immunotherapy combination appears to outweigh the known 
risks of these  agents and warrants clinical investigation. 
3 OBJECTIVES AND ENDPOINTS  
The cohort -specific objectives and endpoints are listed in Table 5.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 26 Table 5:  Cohort -Specific Objectives and Correspondin g Endpoints  
Objectives Endpoints  
Primary   
• To determine the safety of NKTR -214 + nivolumab 
in participants with mCRPC.  Refer to the core protocol . 
Secondary   
• To determine the ORR of NKTR -214 + nivolumab 
in participants with measurable mCRPC.  
• To determin e the DCR ≥  9 months of NKTR -214 + 
nivolumab  in participants with measurable mCRPC.  
• To evaluate the rPFS of NKTR -214 + nivolumab in 
participants with mCRPC.  
• To estimate the OS of NKTR -214 + nivolumab in 
participants with mCRPC.  Refer to the core protocol . 
Exploratory   
• To evaluate the PK of NKTR -214 and/or nivolumab.  
• To evaluate the immunogenicity (ADA) of 
NKTR -214 and/or nivolumab.  
 
Refer to the core protocol  for overall exploratory 
objective(s).  • Sparse PK analysis.  
• Presence of ADA against NKTR -214 and/or 
nivolumab . 
 Refer to the core protocol  for overall exploratory 
endpoint(s).  
ADA = anti -drug antibodies; DCR = disease control rate; mCRPC  = metastatic castration -resistant prostate cancer; 
ORR = objective response rate; OS = overall survival; PK = pharmacokinetics; rPFS = radiographic progression -free 
survival  
 
4 STUDY DESIGN 
4.1 OVERALL DESIGN  
In this study intervention cohort, NKTR -214 and nivolumab will be administered Q3W for up to 
2 years (Figure 1 ), unless the par ticipant: is no longer clinically benefiting (as evidenced by 
[CONTACT_336394]/or clinical deterioration); experiences any 
toxicity meeting specified discontinuation criteria (see Section 6.6) or unacceptable toxicity in 
the best clinical discretion of the treating physician ; reaches th e maximum duration of study 
intervention; or withdraws consent. 
Participants will be monitored for safety and response and will be followed on- study for up to 
2.[ADDRESS_415571] been established as being 
safe, resulting in pharmacodynamic activity and having antitumor activity  in previous and 
ongoing clinical trials ( Section 4.3.2 and Section [IP_ADDRESS], respectively). Further, the proposed 
doses are those currently under study as the recommended phase 2 dose  in Study 16 -214-02, the 
ongoing phase 1/2 study i n subjects  with locally advanced or metastatic solid tumor 
malignancies ( Study 16 -214-02 [PI[INVESTIGATOR_12964] -02 study] ; Diab et al., 2017b; Diab et al., 2018).  
Base d on the safe ty profiles of the individual components , as well as the safety data from the use 
of the combination of NKTR -214 and nivolumab in other disease populations , there does not 
appear to be overlappi[INVESTIGATOR_50685]. Therefore, this combination  at the  doses propos ed is 
considered warranted for the evaluation of safety and efficacy in this population. 
4.3.1 Rationale for Nivolumab  Dose and Schedule  
In the US, single -agent nivolumab was approved in 2014 at a dose of 3 mg/kg every 2 weeks 
(Q2W ). Subsequently, population pha rmacokinetics (PPK) and exposure response analyses were 
performed to support use of flat dosing regimens (ie, nivolumab 240 mg Q2W, 360 mg Q3W, 
and 480 mg every 4 weeks [ Q4W ]) in participants with cancer. A flat dose of nivolumab 240 mg 
Q2W wa s selected since it is identical to a dose of 3 mg/kg for participants weighing 80 kg, the 
observed median body weight in nivolumab- treated cancer patients, while the nivolumab 360 mg 
Q3W and 480 mg Q4W regimens allow flexibility of dosing with less freque nt visits and in 
combination with other agents using alternative dosing schedules to Q2W, such as ipi[INVESTIGATOR_125]. Using a PPK model, the overall distributions of nivolumab exposures (average steady -state 
concentration [Cavgss], minimum steady -state plasma conc entration [Cminss], maximum steady -
state plasma concentration [Cmaxss], and trough concentration after the first dose [Cmin1]) are comparable after treatment with either nivolumab 3 mg/kg or 240 mg Q2W ( Nivolumab 
Invest igator’s Brochure, 2018). The 240 mg Q2W dose was approved in the USPI [INVESTIGATOR_336374] 
2016 for use in metastatic melanoma, NSCLC, and RCC indications. In March 2018, the 480 mg 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 28 Q4W dose was approved in the USPI [INVESTIGATOR_336375], NSCLC, RCC, cH L, 
SCCHN, UC, and HCC indications ( Opdivo USPI, 2018).  
[IP_ADDRESS]  Nivolumab [ADDRESS_415572] ed to be similar to those following nivolumab 
3 mg/kg or 240 mg Q2W, while Cminss are predicted to be 6% lower and are not considered to 
be clinically relevant. Cmaxss are predicted to be approximately ~23% greater relative to that following nivolumab 3 mg /kg Q2W dosing. However, the range of nivolumab exposures 
(median and 90% prediction intervals) following administration of 240 mg flat Q2W, 360 mg Q3W, and 480 mg Q4W regimens across the 35 to 160 kg weight range are predicted to be maintained well below the corresponding exposures observed with the well tolerated 10 mg/kg nivolumab Q2W dosing regimen. This less frequent dosing regimen (ie, Q3W vs Q2W) is 
designed to afford greater convenience to the target patient population and allow combination of 
nivol umab  with other agents ( Nivolumab Investigator ’s Brochure, 2018).  
4.3.2 Rationale for NKTR -214 D ose and Schedule  
The clinical pharmacology profile of single -agent NKTR -214 was assessed in Study 15 -214-01 
(Study 15- 214-01 [EXCEL] ). NKTR -214 was administered as a 15 -minute intravenous infusion 
at dose levels of 0.003, 0.006, 0.009, and 0.012 mg/kg every 2 weeks (Q2W) or Q3W. The maximum tolerated dose (MTD) of NKTR -214, based on pre -defined dos e limiting toxicity 
(DLT) criteria, was 0.009 mg/kg administered Q3W. Blood samples were analyzed for NKTR -
214 related cytokines (NKTR -214-RC), NKTR -214 active cytokines (NKTR -214-AC), 
unconjugated IL -2, and PEG to characterize the pharmaco kinetics ( PK) and metabolism of 
NKTR -214 ( NKTR -214 Investigator’s Brochure, 2018).  
Maximal concentrations of NKTR -214-RC were achieved shortly after the end of the first 
infusion of NKTR -214 and declined monoexponentially thereafter, re maining detectable for 8 to 
11 days postdose and resulting in mean half -life values between 13 and 19 hours across dose 
levels. NKTR -214-RC maximum plasma concentrations (Cmax) and area under the curve (AUC) 
increased linearly with dose.  
NKTR -214-AC concentrations increased gradually after dosing, achieving a mean time to Cmax 
(Tmax) between 26 and 30 hour s postdose. After reaching Cmax, NKTR -214-AC declined 
monoexponentially in parallel to the decline in NKTR -214-RC, and remained detectable for 8 
days pos tdose, resulting in mean half -life values between 13 and 23 hours.   
NKTR -214-RC and NKTR -214-AC exposure were similar across participant s within a dose 
cohort and between cycles, without indication of accumulation with either the Q3W or Q2W 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 29 administration  schedules, as expected based on the half -life. NKTR -214-AC and NKTR -214-RC 
exposure increased linearly  with dose over the dose range studied.  
Unconjugated IL -2 was only sporadically detected, and when detected, was present only at low 
concentrations (0.5 to 7.1 ng/mL, with the majority near the quantitation limit of 0.5 ng/mL) 
indicating that unconjugated IL-[ADDRESS_415573] of nivolumab on NKTR -214 PK was assessed in Study 16- 214-02 (PI[INVESTIGATOR_12964] -02), based 
on NKTR -214-RC exposure. Pharmacokinetics of NKTR -214-RC in combination with 
nivoluma b appear similar to those after NKTR -214 monotherapy, suggesting no drug- drug 
interaction between NKTR -214 and nivolumab ( NKTR -214 Investigator’s Brochure, 2018).  
4.[ADDRESS_415574] participant to the end of the 
cohort, is expected to be approximately 3 years, 9 months. 
5 STUDY POPULATION  
Prospective requests for approval of protocol deviations to recruitment and enrollment criteria, 
also known as waivers or exemptions, is not all owed. 
5.1 INCLUSION CRITERIA 
Participant s are eligible to be included in the study only if all the following criteria apply:  
5.1.[ADDRESS_415575] be  ≥ [ADDRESS_415576] dose of study intervention and refrain from donating sperm 
during this period.  
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for 
the participant.  
3. Participants must be able and willing to comply with the study visit schedule and study procedures.  
4. Histologically documented adenocarcinoma of  the prostate.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 30 5. Metastatic castration resistant prostate cancer with castrate -level testosterone 
(< 50 ng/dL ) at screening . 
6. Have received and progressed on prior secondary androgen receptor signaling inhibitor 
therapy (eg , abiraterone, enzalutamide, apaluta mide). Progression is defined by [CONTACT_113397] 3 criteria:  
a. Prostate -specific antigen ( PSA) ≥ 1.0 ng/mL and rising PSA by [CONTACT_2669] 2 
consecutive measurements a minimum of 1 -week apart.  
b. Soft tissue progressi on as defined by [CONTACT_119549] (RECIST) version 1.1 ( Eisenhauer et al., 2009).  
c. Bone disease progression as defined by 2 new bone lesions (as per Prostate Cancer Clinical Trials Working Group 3 [ PCWG3 ; Scher  et al., 2016] ).  
7. Have measurable disease or non- measurable disease based on PCWG3 -modified 
RECIST  1.1. 
8. Provide fresh pre -treatment core needle or incisional biopsy of a metastatic tumor lesion 
not previously irradiated. Fine needle aspi[INVESTIGATOR_123453].  
a. Additionally, if a pre -treatment biopsy is not medically feasible for participants 
with bone only  disease, formalin -fixed paraffin -embedded (FFPE) tumor 
specimen in a paraffin block (preferred) or at least [ADDRESS_415577] be willing to undergo tumor biopsy (ies) on treatment , if medically feasible.  
10. Participa nts must discontinue antiandrogen therapy (ie, bicalutamide, flutamide, 
nilutamide) at least 4 -6 weeks prior to registration with no evidence of PSA decline after 
washout. 
a. Bicalutamide: Washout period at least 6 weeks  
b. Flutamide and nilutamide: Washout peri od at least [ADDRESS_415578] discontinue therapi[INVESTIGATOR_336376] 5 half -lives or 28 days, whichever 
is shorter.  
a. Participants will remain on gonadotropin- releasing hormone  (GnRH)  agents 
throughout this study.  
b. Prior chemotherap y is allowed if no pro gression of disease on chemotherapy as 
defined by [CONTACT_43877]3- modified RECIST 1.1.  
c. Prior treatment with sipuleucel- T, radium -223, or poly a denosine diphosphate  
(ADP )-ribose polymerase  (PARP ) inhibitor  (eg, olaparib) is allowed.  
d. Tissue biopsy may be performed during washout period. 
12. Participants with prior or concurrent malignancies are permitted if any one of the following applies:  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 [ADDRESS_415579] 2 years before enrollment and no evid ence of disease exists, or  
b. With agreement from the Medical Monitor and P rincipal Investigator (PI), 
participants who have a concurrent malignancy that is clinically stable and does not require tumor -directed treatment are eligible to participate if the ris k of the 
prior malignancy interfering with either safety or efficacy endpoints is very low, or 
c. With agreement from the Medical Monitor  and PI, other malignancies may be 
permitted if the risk of the prior malignancy interfering with either safety or  
efficac y end points is very low.  
13. Have a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale.  
14. Demonstrate adequate organ function on screening laboratory tests performed within 14 days of treatment initiation and as eviden ced by:  
a. Hemoglobin ≥ 9.0 g/dL or ≥ 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within ≤  7 days of assessment)  
b. Absolute neutrophil count ≥ 1,500/mm
3 withou t growth factor support (within 
< 28 days of assessment)  
c. Platelet count ≥ 100,000/mm3 
d. Estimated glomerular filtration rate (GFR) ≥  45 mL/min using the Cockcroft -
Gault formula  
e. Serum total bilirubin < 1.5 x upper limit of normal (ULN)  or ≤  2.[ADDRESS_415580] for 
participants with liver metastases  
i. Participants with Gilbert's syndrome must have ≤  [ADDRESS_415581]  and no liver 
lesions  
f. Aspartate aminotransferase  (AST) (SGOT) and alanine aminotransferase (ALT) 
(SGPT) ≤  3.[ADDRESS_415582] or ≤ 5.[ADDRESS_415583] for participants with liver metastases.  
g. Albumin ≥  2.5 mg/dL.  
h. International normalized ratio (INR) or prothrombin time (PT) ≤  1.[ADDRESS_415584] 
unless participant is receiving anticoagulant therapy, as long as PT is within therapeutic range of intended use of anticoagulants.  
i. Activated partial thromboplastin time (aPTT) ≤  1.[ADDRESS_415585] unless participant is 
receiving anticoagulant therapy, as  long as PTT is within therapeutic range of 
intended use of anticoagulants. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 32 15. Willing and c apable of giving signed informed consent as described in Appendix 1 of the 
core protocol , which includes compliance with the requirements and restrictions listed in 
the informed consent form (ICF) and in this protocol. 
 
5.1.2 Combination -specific Inclusion Criteria  
1. A documented left ventricular ejection fraction (LVE F) > 45% using standard 
echocardiogram  (ECHO)  or multigated acquisition (MUGA) scan test within 60 days 
prior t o Cycle 1 Day 1.  
2. Oxygen saturation ≥ 92% on room air.  
 
5.2 EXCLUSION CRITERIA 
Participant s are excluded from the study if any of the following criteria apply:  
5.2.[ADDRESS_415586] dose of treatment.  
a. Recent or concurrent non -therapeutic investigational agents that are not 
anticipated to interfere with study intervention, such as certain investigational imaging tracers, may be permitted with written agreement from the Medical Monitor. 
2. Has a diagnosis of immunodeficiency or conditions that need systemic corticosteroid replacement therapy > 10 mg/day prednisone (or equivalent) or other immunosuppressive medications within [ADDRESS_415587] dose of study intervention. Inhal ed steroids 
are permitted if necessary.  
3. Has any active known or suspected autoimmune disease. Participants with vitiligo, type I diabe tes mellitus, controlled autoimmune hypothyroidism, psoriasis not requiring 
systemic treatment, or other conditions under control are permitted to enroll. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy ≤ 10 m g of prednisone/day for adrenal or pi[INVESTIGATOR_13002], etc.) is not 
considered a form of systemic treatment.  
4. Has a k nown history of active TB ( Bacillus Tuberculosis ). 
5. Has known history of, or any evidence of active, non- infectious pneumonitis. 
6. Has an active infection requiring systemic therapy.  
7. Has a history or current evidence of any condition, therapy, or laboratory a bnormality 
that might confound the results of the trial, interfere with the participant’s participation 
for the full duration of the trial, or is not in the best interest of the participant to participate, in the opi[INVESTIGATOR_12980]. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 [ADDRESS_415588] dose of study intervention . 
10. Known history of testing positive for human immunodeficiency virus (HIV), known acquired immunodeficiency syndrome (AIDS), or any positive test for hepatitis B or hepatitis C virus representing acute or ch ronic disease.  
11. Has received a live vaccine within 30 days of planned start of study intervention. 
Note:  Seasonal influenza vaccines for injection are generally inactivated flu vaccines and 
are allowed; however intranasal influenza vaccines (eg, Flu -Mist®)  are live attenuated 
vaccines, and are not allowed.  
12. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are stable (without evidence of progression by [CONTACT_89181] [ADDRESS_415589] returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to study intervention.  This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.   
13. Has had a prior anti -cancer monoclonal antibody (mAb) within 4 weeks prior to study 
Day 1 or who has not recovered (ie, ≤  Grade 1 or at baseline) from AEs  due to agents 
administered more than 4 weeks earlier.  
a. Participants with controlled autoimmune disease  as described in exclusion 
criterion #3 are permitted to enroll.  
14. Has had prior chemotherapy, targeted small molecule ther apy, or radiation therapy within 
2 weeks prior to study Day 1 or who has not recovered (ie, ≤ Grade 1 or at baseline) from AEs due to a  previously administered agent.  
a. Note:  Participants with ≤ Grade 2 neuropathy  and/or hearing loss  are an 
exception to thi s criterion and may qualify for the study.  
b. Note:  If a participant received major surgery, he must have recovered adequately from the t oxicity and/or complications from the intervention prior to starting 
therapy.   
15. History of allergy to any of the study in tervention components. 
 
5.2.[ADDRESS_415590] received prior IL -2 therapy.  
2. Has had prior t herapy with any anti -PD-1 or anti -PD-L1 antibody (prior therapy with an 
anti-cytotoxic T -lymphocyte -associated protein 4 [CTLA -4] antibody is permitted).  
3. Prolonged Fridericia’s corrected QT interval (QTcF) > 450 ms at screening . 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 34 4. History of unstable or dete riorating cardiac disease within the previous 6 months prior to 
screening including but not limited to the following:  
a. Unstable angina or myocardial infarction  
b. Congestive heart failure ([LOCATION_001] Heart Association [NYHA] Class III or IV)  
c. Uncontrolled clinica lly significant arrhythmias  
5. Need for > 2 antihypertensive medications for management of hypertension (including 
diuretics) . 
 
5.[ADDRESS_415591]  2 liters per 
day of self -administered oral hydration on Days 2 to 5 are recommended . 
5.3.2 Activity 
As part of the protocol hydration guidelines, participants  should be advised to restrain from 
strenuous ac tivity and avoid long hot showers and saunas for Days 1 to 5 of every cycle.   
5.4 SCREEN FAILURES  
Refer to the core protocol . 
6 STUDY INTERVENTION 
Study intervention is defined as any investigational intervention(s), marketed product(s)  or 
placebo intended to b e administered to a study participant  according to the study protocol.  
6.1 STUDY INTERVENTION(S) ADMINISTERED 
The study interventions to be administered in this study are summarized in  Table 6.  
Table 6:  Study Intervention  
Study  
Intervention  
Name  [CONTACT_336407](s)  Dosage 
Level(s)  Route of 
Administration  Sourcing  
NKTR -214 Sterile lyophilized powder to be 
reconstituted with sterile water 
for injection  and diluted with 
commerc ially available dextrose  
5% or normal  saline  1.0 mg/mL 
of IL -2 0.006 mg/kg  IV infusion  Nektar 
Therapeutics  
Nivolumab  Aqueous solution  10 mg/mL  360 mg IV infusion  Bristol- Myers 
Squibb 
IV = intravenous  
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 35 NKTR -214 0.006 mg/kg will be administered as an IV infusion over approximately 30 minutes  
(± 5 minutes)  (see Section 4.3.2) , followed approximately 30 minutes  later by [CONTACT_20382] 360 
mg, administered as an IV infusion over approximately 30 minutes  (see Section [IP_ADDRESS]) . Study 
intervention will be administered Q3W for up to 2  years, unless the participant: is no longer 
clinically benefiting (as evidenced by [CONTACT_336400] d/or 
clinical deterioration); experiences any to xicity meeting specified discontinuation criteria  (see 
Section 6.6)  or unacceptable toxicity in the best clinical discretion of the treating physician; 
reaches the maximum duration of study intervention; or  with draws consent. A cycle is defined as 
3 calendar weeks.  
The NKTR -214 dose will be determined by [CONTACT_2299]’s weight in kilograms, which will be 
determined before the start of each 3- week cycle. If the participant ’s weight is within 10% of the 
participa nt’s weight  on Day 1 of Cycle 1, the study drug dose  does not need to be recalculated, 
depending on institutional guidelines/preference.  
Adm inistration of study intervention will be performed in a monitored setting in which there is 
immediate access to tra ined personnel and adequate equipment and medicine to manage 
potentially serious reactions. 
6.1.[ADDRESS_415592] 1 liter of IV fluid on will be administered 
prior to NKTR -214 administration on the day of each NKTR -214 dos e. For the ne xt 3 days after 
administration  (ie, Days 2 – 4 of each cycle) , participants should be instructed that they are 
requi red to drink at least 2 liters per day of self -administered oral hydration  (note: al cohol and  
caffeine intake should not be counted toward t he daily hydration requirements) . Participants 
should be advised to restrain from strenuous activity and avoid long hot showers and saunas for 
Day [ADDRESS_415593] of the participant (eg, evidence of fluid 
overload).  
Participants should be advised to call their trea ting oncologist if they experience  orthostatic 
symptoms and consider increasing oral hydration.  
To mitigate the event of hypotension, consideration should be  given to withholding 
antihypertensive medications, including diuretics, as well as other drugs with hypotensive 
properties as described Section  6.5.2. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 36 6.2 PREPARATION/HANDLING/STORAGE/ACCOUNT ABILITY  
Refer to the core protocol  for general guidance on  handling , storage, and accountability.  
NKTR -[ADDRESS_415594] should be stored in a secure, locked area with temperature at monitored 
-20 °C (± 5 °C), as specified on the drug label.  
Nivolumab must be stored at 2 °-8°C and protected from light and freezing.  
The instructions for reconstitution and administration of the study intervention are described in 
the Pharmacy Manual(s).  
6.3 RANDOMIZATION AND BLINDING  
This is not a randomized study, and study inter vention will be administered in an open- label 
fashion. 
6.4 STUDY INTERVENTION COMPLIANCE  
Study intervention will be administered by [CONTACT_336401]. No additional measures of compliance will be  instituted . 
6.5 CONCOMITANT THERAPY  
Refer to the core protocol . 
6.5.1 Permitted Therapy  
Refer to the core protocol . 
6.5.2 Prohibited Therapy  
Refer to the core protocol . 
In addition to the prohibited therapy described in the core protocol , based on clinical evidence, 
the Investigato r may decide to withhold antihypertensive medications , including diuretics, as 
well as other drugs with hypotensive properties (eg, alpha blockers for benign prostatic hypertrophy) prior to each dose of NKTR -214, particularly when therapy involves multiple  anti-
hypertensive drugs and classes other than thiazide diuretics. If discontinuing antihypertensive medications, discontinue no less than 12 hours and no more than 48 hours prior to each dose of NKTR -214. Antihypertensive medications may be reinstituted in between doses of NKTR -214 if 
the diastolic pressure exceeds 90 mm Hg and/or the systolic pressure exceeds [ADDRESS_415595] any dose escalation or dose reduction of nivolumab in this 
study; dose reduction, but not dose escalation, of NKTR -214 is allowed.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 37 Participants who experience an AE described in Table 7 will be permanently discontinued from 
all study intervention and should continue follow -up assessments as outlined in the S OA 
(Section 1.3) . 
Grade 3 and 4 toxicities are observed in all trials of nivolumab in multiple tumor types. As such 
toxicities are antic ipated ; how ever, given the unique nature of this protocol, monitoring for AEs 
described in Table [ADDRESS_415596] of NKTR -214 and nivolumab on the AE or immune -related AE  (irAE) profiles 
of these agents continues to evolve . Guidance with respect to the individual agents is provided in 
Section  6.6.2 and Section  6.6.3. Refer to the USPI [INVESTIGATOR_336377] ( Opdivo USPI, 2018)  and the  
Investigator ’s Brochures for nivolumab a nd NKTR -214 for complete summaries of safety 
information . 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 38 Table 7:  Toxicity Criteria Requiring Permanent Treatment Discontinuation  
Participants should be monitored for the occurrence of any of  the following AEs that are considered by [CONTACT_70563], probably, or definitely related to  nivolumab, NKTR -214, or the immunotherapy 
combination. Treatment  with all study intervention should be permanently discontinued for the following:  
• Grade 4 non -hematological toxicity (not laboratory)  
• Grade 4 hematologic toxicity lasting ≥  7 days  or that is clinically significant  
• Grade 3 thrombocytopenia in the presence of clinically significant active bleeding (eg, requiring 
transfusion or hospi[INVESTIGATOR_059])  
• Any non- hematologic toxicity  ≥ Grade 3 in severity, with the following exceptions:  
o Endocrinopathy AEs, such as adrenal insufficiency, adrenocorticotropic hormone (ACTH) deficiency, hyper - or hypothyroidism, that resolve or are adequately c ontrolled with physiologic hormone 
replacement (corticosteroids, thyroid hormones) or glucose intole rance managed with glucose -
controlling agents  
o Amylase or lipase elevations that last ≤ 7 days  
o Electrolyte imbalances/abnormalities that are not associated with clinical sequelae and are corrected with supplementation/appropriate management within 72 hours of their onset  
o Tumor flare defined as local pain, irritation, or rash localized at sites of known or suspected tumor  
o Grade 3 nausea,  vomiting, o r diarrhea  that can be medically managed to ≤ Grade 2 within 72 hours  
o Grade 3 hypotension during Cycles 1 or 2 that lasts ≤  [ADDRESS_415597] -dose 
o Fatigue that im proves to ≤  Grade [ADDRESS_415598] of care 
• Any new Grade 3 or Grade 4 non- hematologic laboratory abnormality, if  
o the abnormality leads to hospi[INVESTIGATOR_059], or  
o the abnormality persists for > 1 week  and is believed to be clinically significant. For example, 
exceptions would include asymptomatic pancreatitis.  
• Febrile neutropenia Grade 3 or Grade 4  
• Any elevated AST or ALT laboratory value that is ≥ 3 × ULN and an elevated total bil irubin lab value that 
is ≥ 2 × ULN and an alkaline phosphatase lab value that is < 2 × ULN, in whi ch no alternative reasons can 
be found to explain the combination of increased AST/ALT and total bilirubin, such as viral hepatitis A, B or C, preexisting or acute liver diseases, pre- existing known liver metastases, or another drug capable of 
causing the observed injury 
• Grade 5 toxicity  
ACTH = adrenocorticotropic hormone ; AE(s) = adverse event(s); A LT = alanine aminotransferase; AST = aspartate 
aminotransfera se; ULN = upper limit of normal  
 
 
[IP_ADDRESS]  Potential for Overlappi[INVESTIGATOR_336368] -[ADDRESS_415599] ered in combination. 
The safety data for nivolumab are described in the USPI  (Opdivo USPI, 2018). Nivolumab 
therapy is associated with immune -mediated adverse reactions, which can be se vere and fatal in 
some cases. With appropriate medical therapy, immune -related adverse reactions resolved in 
most cases. Immune -mediated adverse reactions may involve any organ system; however, the 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 [ADDRESS_415600] common severe immune -mediated adverse reactions are enterocolitis, endocrinopathies, 
hepatitis, dermatitis (including toxic epi[INVESTIGATOR_336378] -Johnson syndrome), and 
neuropathy. The safety profile of nivolumab combination therapy varies with the  agent combined 
with nivolumab but is generally co nsistent with the safety profiles o bserved with either agent 
alone and, in some cases, both frequency and severity of AEs were greater than that  observed 
with either agent alone.  
Cytokine -related toxicity is the most common toxicity observed in patients tr eated with 
NKTR -214 monotherapy and NKTR -214 in combination with nivolumab. These toxicities, 
reported either as stand -alone  clinical diagnos es or as the associated individual signs and 
symptoms, including flu- like symptoms, rash, pruritus, cytokine releas e syndrome, fatigue, and 
elevated hepatic transaminases are generally mild or moderate in severity, and are self -limiting.  
Thyroid dysfunction, reported as hypothyroidism, thyroiditis (may be characterized by [CONTACT_336402]), or hyperthyroidism,  occurred primarily in 
patients receiving combination therapy  with NKTR -[ADDRESS_415601] of IL -2 therapy.  The frequency of selected AEs (primaril y Grade 1 or 2 in 
severit y) such as  rash, pruritus, edema, nausea, vomiting, diarrhea and dizziness increased with 
level of eosinophilia. Isolated cases of suspected hypereosinophilic syndrome have been 
reported. Absolute eosinophil count should be closely  monitored per protocol. 
[IP_ADDRESS]  Dose Modifications and Toxicity Management for Adverse Events 
Associated with Nivolumab and NKTR -214 
Immuno- oncology agents are associated with AEs that can differ in severity and duration from 
AEs caused by [CONTACT_336403]. Early recognition and management of AEs associated 
with immuno -oncology agents may mitigate severe toxicity. Management algorithms ( Appendix  
A-1) have been developed to assist Investigators in assessing and managing the following drug -
related AEs.  
• Immune -mediated colitis  
• Immune -mediated nephritis and renal dysfunction  
• Immune -mediated pneumonitis  
• Immune -mediated hepatitis  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 40 • Immune -mediated endocrinopathies (hypophysitis, adrenal insufficiency, hypothyroidism 
and hy perthyroidism, Type 1 diabetes mellitus)  
• Immune -mediated skin adverse reactions  
• Immune -mediated encephalitis  
 
[IP_ADDRESS]  Dose Modifications and Toxicity Management for Infusion -
related Reactions Associated with  the Administration of  
NKTR -214 and/or  Nivolumab  
Interrup t or slow the rate of infusion in participants with mild or moderate infusion reactions. 
Discontinue the  immunotherapy combination i n participants with severe or life -threate ning 
infusion reactions.  
All Grade 3 or 4 infusion reactions should be reported wi thin 24 hours to the study Medical 
Monitor and reported as a  serious adverse event ( SAE ) if it meets the criteria. Infusion reactions 
should be graded as described in Section  10.5.3 of the core protocol . 
Dose modification and toxicity management guidelines  for infusion- related reactions are 
provided in Table 8.  
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0 033 Appendix Amendment 1, Version 2.0 41 Table 8:  Dose Modification and Toxicity Management Guidelines for Infusion -related Reactions Associated with the 
administration of NKTR -214 and/or  Nivolumab  
Grade  
(NCI CTCAE v 5.0)   
Treatment  Premedication at 
Subsequent Dosing  
Grade 1  
Mild reaction; infusion interruption not indicated; 
intervention not indicated  Increase monitoring of vital signs as medically indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_336379] 2  
Requires therapy or infusion interruption but responds promptly to symptomatic treatment (eg, antihistamines, 
NSAIDs, narcotics, IV fluids); prophylactic medications indicated for ≤  24 hours  Stop Infusion  
Additional appropriate medical therapy may include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDs  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as medically indicated until the participant is 
deemed m edically stable in the opi[INVESTIGATOR_336380] 1 hour of stoppi[INVESTIGATOR_13056], the inf usion may 
be restarted at 50% of the original infusion rate (eg, from 100 mL/h to 50 mL/h).  
Otherwise dosing will be held until symptoms  resolve and the participant should 
be premedicated for the next scheduled dose 
Participants who develop Grade 2 toxici ty despi[INVESTIGATOR_336381] 3 or 4  
Grade 3 : 
Prolonged (ie, not rapi[INVESTIGATOR_13081]/or brief interruption of infusion); 
recurrence of symptoms following initial improvement; 
hospi[INVESTIGATOR_336382] (eg, 
renal impairment, pulmonary infiltrates)  
Grade 4 : 
Life-threatening; pressor or v entilatory support indicated  Stop Infusion  
Administer urgent medical therapy as appropriate/clinically indicated  
Increase monitoring of vital signs as medi cally indicated until the participant is 
deemed medically stable in the opi[INVESTIGATOR_336383]  
**In cases of anaphylaxis, epi[INVESTIGATOR_336384] a physician readily available during the period of drug administration.  
For further information, please refer to the Common Terminology Criteria  for Adverse Events v5.0 (CTCAE) at http://ctep.cancer.gov  
CTCAE = Common Terminology Criteria for Adverse Events ; NCI = National Cancer Institute; NSAIDs = nonsteroidal anti -inflammatory drugs;  IV = intravenous  
 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 42 [IP_ADDRESS]  Dose Delays and Interruptions of NKTR -214 + Nivolumab 
Combination Immunotherapy  
Dose delays and interruptions are pe rmitted for toxicity reasons (see  Section 6.6.2 and 
Section  6.6.3).  
The Investigator may at tribute each AE to the combination or to either individual intervention. 
• If, in the opi[INVESTIGATOR_689], the toxicity is related to the combination of the 
agents, then all drugs should be held according to recommended dose modifications. 
• If the tox icity is considered clearly related to [ADDRESS_415602] be discontinued from the combination 
therapy.  
Dose delays and interruptions f or reasons other than toxicity, such as surgical procedures, may 
be allowed with Medical Monitor approval. The acceptable length of interruption will depend on agreem ent between Investigator and Medical Monitor. 
6.6.2 Dose Modifications for Nivolumab  
This study will include set dosing for nivolumab (360 mg Q3W). Dose escalation or reduction of 
nivolumab will not be allowed. If toxicity does not resolve or the criteria for re suming study 
intervention are not met within  [ADDRESS_415603] included pul monary toxicity, renal toxicity (including acute renal failure), endocrine 
abnormalities, gastrointestinal toxicity, dermatologic toxicity (including rash), and hepatotoxicity. For nivolumab monotherapy, as well as when administered in combination, the 
majority of these AEs have been managed successfully with supportive care and, in more severe 
cases, a combination of dose delay, permanent discontinuation, and/or use of corticosteroids or 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 43 hormone re placement therapy (endocrinopathies). For suspected irAEs, ensure adequate 
evaluation to confirm etiology or exclude other causes. Additional procedures or tests such as 
bronchoscopy, endoscopy, and skin biopsy may be included as part of the evaluation.  
Dose modification and toxicity management guidelines for irAE s associated with nivolumab are 
provided in Table 9.  
Table 9:  Dose Modification  and Toxicity Management Guidelines for Adverse Events 
Associated with Nivolumab  
Adverse Reaction  Severitya Dose Modifications  
Colitis  Grade  2 diarrhea or colitis  Withhold doseb 
Grade 3 diarrhea or colitis  Withhold doseb  
Grade 4 diarrhea or colitis  Permanently discontinue  
Pneumonitis  Grade 2 pneumonitis  Withhold doseb 
Grade 3 or 4 pneumonitis  Permanently d iscontinue  
Hepatitis/non -HCC  Aspartate aminotransferase (AST) or alanine 
aminotransferase (ALT) more than 3 and up 
to 5 times the upper limit of normal (ULN) or total bilirubin more than 1.[ADDRESS_415604]  Permanently discontinue  
Hepatitis/HCC  • If AST/ALT is within normal limits at 
baseline and increases to more than [ADDRESS_415605]  
• If AST/ALT is more than [ADDRESS_415606]  
• If AST/ALT is more than [ADDRESS_415607]  Permanently discontinue  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 44 Adverse Reaction  Severitya Dose Modifications  
Skin Grade 3 rash or suspected Stevens -Johnson 
syndrome (SJS) or toxic epi[INVESTIGATOR_7387] (TEN)  Withhold doseb 
Grade 4 rash or confirmed SJS or TEN  Permanently discontinue  
Encephalitis  New onset moderate or severe neurologic 
signs or symp toms  Withhold doseb 
Immune -mediated encephalitis  Permanently discontinue  
Other  Other Grade 3 adverse reaction  
• First occurrence  
• Recurrence of the same Grade 3 adverse reaction   
Withhold d oseb 
Permanently discontinue  
Life-threatening or Grade 4 adverse reaction  Permanently discontinue  
Grade 3 myocarditis  Permanently discontinue  
Requirement for 10 mg per day or greater 
prednisone or equivalent for more than 12 
weeks  Permanently discont inue 
Persistent Grade 2 or 3 adverse reactions 
lasting 12  weeks or longer  Permanently discontinue  
Source: Opdivo USPI, 2018  
ALT = alanine aminotransferase; AST = a spartate aminotransferase;  HCC = hepatocellular carcinoma; 
SJS = Stevens -Johnson syndrome; TEN = toxic  epi[INVESTIGATOR_194]; ULN = upper limit of normal  
a Guidelines based on t oxicity graded per National Cancer Institute Common Terminology Criteria for A dverse 
Events (NCI CTCAE), where applicable.  
b Resume treatment when adverse reaction improves to Grade [ADDRESS_415608]/ALT return (s) to baseline.  
 
6.6.3 Dose Modifications for NKTR -214 
Dose delays and reductions are permitted for NKTR -214. Per recommendation of the 
Investigator and approval of the Sponsor’s Medical Monitor, NKTR -214 dose may be delayed or 
reduced to 0.003 mg/kg based on observed drug -related toxicities. If the NKTR -214 dose is 
reduced to 0.003 mg/kg, the dose should remain at this level throughout the remainder of the 
study.  
NKTR -214 may be delayed or reduced for the following reasons (considered to be related to 
NKTR -214):  
• Grade 1 or 2 toxicity:  No requirement for dose  delay or dose reduction.  If the toxicity 
persists at Grade 2 following completion of Cycle 1, a dose delay or dose reduction may be implemented at the discretion of the Investigator with the approval of the Medical 
Monitor. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 45 • Grade 3 toxicity:  NKTR -214 ma y be withheld if toxicity cannot be managed by [CONTACT_336404]. NKTR -214 dosing may resume at the same NKTR -214 dose or at a 
lower NKTR -214 dose level when toxicity resolves to Grade 1 or returns to baseline, 
except for instances where the po tential recurrence of the event poses an undue risk for 
the participant.  
If NKTR -214 is delayed, nivolumab adm inistration can continue unless toxicity related to 
nivolumab would warrant a dose delay.   
Participants will be permitted to resume study drug(s)  at the same dose level(s) following 
resolution of an AE to ≤ Grade [ADDRESS_415609] dose, with the 
exception of participants who meet criteria for permanent discontinuation as specified in 
Section  [IP_ADDRESS]. Participants who meet criteria for permanent discontinuation  of NKTR -[ADDRESS_415610] 
perman ently discontinue all study intervention.  
If the decision is made to resume study drug(s) dosing, the participant should restart treatment on the next regularly scheduled study drug(s) dosing visit.  Skipped doses are not to be replaced.  
Participants may r esume treatment when the drug -related AE(s) resolve(s) to ≤ Grade 1 or 
basel ine, with the following exceptions:  
• Participants may resume treatment in the presence of Grade 2 fatigue.  
• Participants with baseline Grade [ADDRESS_415611]/ALT or total bilirubin who require dose delays 
for reasons other than a [ADDRESS_415612]/ALT or total bilir ubin may resume 
treatment in the presence of Grade [ADDRESS_415613]/ALT or total bilirubin.  
• Participants with combined Grade [ADDRESS_415614]/ALT and total bilirubin values meeting 
discontinuation param eters ( see Section [IP_ADDRESS]) should have treatment permanently 
discontinued. 
• Drug -related pulmonary toxicity, diarrhea, or colitis must have resolved to baseline 
before treatment is resumed. Participants with per sistent Grade  [ADDRESS_415615] 1 month may be eligible to resume study 
drug(s) treatment if discussed with and approved by [CONTACT_1689].  
• Drug -related endocrinopathies adequately controlled with only phy siologic horm one 
replacement may resume treatment after consultation with the Medical Monitor.  
 
Dose delay of NKTR -214 that results in treatment delay of > 6 weeks requires treatment 
discontinuation, with exceptions as noted in Section [IP_ADDRESS]. However, if the toxicity resolves to 
≤ Grade 1 or baseline > [ADDRESS_415616] dose, but the participant does not otherwise meet 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 46 the criteria for permanent discontinua tion (see  Section [IP_ADDRESS]), and the Investigator believes that 
the participant is deriving clinical benefit, then the participant may be eligible to resume 
treatment with NKTR -214.  
[IP_ADDRESS]  Permanent Treatment Discontinuation Criteria  
Participants meeting any of the fo llowing criteria attributed to NKTR -214 will be required to 
permanently discontinue all treatment with NKTR -214. However, with Medical Monitor 
approval, NKTR -214 treatment may continue if the toxicities listed below are considered related  
to nivolumab only , provided the event does not meet criteria for delaying or  discontinuation of 
nivolumab (see Section 6.6.2).  
• Disease progression in the absence of clinical benefit (see details regarding continuing treatment b eyond initial assessment of progression per PCWG3 -modified RECIST 1.1 in 
Section 4.4 of the core protocol ). 
• Clinical deterioration, as assessed by [CONTACT_18413].  
• Any Grade 2 drug -related uveitis, eye pain, or blurred vision that does not respond to 
topi[INVESTIGATOR_20308] 1 severity within 6 weeks or requires 
systemic treatment.  
• Any ≥ Grade 2 drug -related pneumonitis or interstitial lung disease that does not resolve 
following dose delay and systemic steroids (also see Pulmonary Adverse Event Management Algorithm in A ppendix  A-1). 
• Any Grade 3 nonskin, drug -related AE lasting > 7 days, with the following exceptions for 
uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic toxicity, 
hypersensitivity reactions, infusion reactions, endocrinopathies, and laboratory 
abnormalities:  
o Grade 3 drug -related uveitis, pneumonitis, bronchospasm, diarrhea, colitis, neurologic 
toxicity, hypersensitivity reaction, or infusion reaction of any duration requires discontinuation. 
o Grade 3 drug -related endocrinopathies adequately controlled with only physiologic 
hormone replacement do not require discontinuation. 
o Grade 3 drug -related laboratory abnormalities do not require treatment 
discontinuation except:  
 Grade 3 drug -related thrombocytopenia > 7 days associated with clinically 
significant bleeding requires discontinuation. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 47  Any drug -related liver function test abnormality that meets the following criteria 
require discontinuation (also see Hepatic Adverse E vent Management Algorithm 
in Appendix  A-1): 
­ AST or ALT > 5 × to 10 × ULN for > 2 weeks  
­ AST or ALT > 10 × ULN  
­ Total bilirubin > 5 × ULN  
­ Concurrent AST or ALT > 3 × ULN and total bilirubin > 2 × ULN  
• Any Grade 4 drug -related AE or labor atory abnormality, except for the following events, 
which do not require discontinuation:  
o Grade 4 neutropenia ≤ 7 days  
o Grade 4 lymphopenia or leukopenia ≤ 14 days in duration 
o Isolated Grade 4 amylase or lipase abnormalities that are not associated with 
symptoms or clinical manifestations of pancreatitis and decrease to < Grade 4 or 
return to ba seline within 7 days.  
o Isolated Grade 4 electrolyte imbalances/abnormalities that are not associated with 
clinical sequelae and are corrected with supplementation/appr opriate management 
within 72 hours of their onset  
o Grade 4 drug -related endocrinopathy AEs such as adrenal insufficiency, 
adrenocorticotropic hormone deficiency, hyper - or hypothyroidism, or glucose 
intolerance, that resolve or are adequately controlled wit h physiologic hormone 
replacement (corticosteroids at ≤ 10 mg of prednisone or equivalent per day, thyroid 
hormones) or glucose -controlling agents, respectively, may not require 
discontinuation after discussion with and approval from the Medical Monitor. 
• Any AE, laboratory abnormality, or intercurrent illness that, in the judgment of the 
Investigator, presents a substantial clinical risk to the participant with continued treatment.  
• Any dosing delay lasting > [ADDRESS_415617] dose, with the following exceptions:  
o Dosing delays to allow for prolonged steroid tapers to manage drug- related AEs are 
allowed. Prior to re -initiating treatment in a participant with a dosing delay lasting 
> [ADDRESS_415618] be consulted.  Tumor assessments should continue as per protocol even 
if dosing is delayed.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 48 o Dosing delays >  [ADDRESS_415619] dose that occur for nondrug -related reasons, 
may be allowed if approved by [CONTACT_1689]. Prior to r e-initiating treatment in 
a participant with a dosing delay lasting > [ADDRESS_415620] otherwise meet the criteria for continued treatment at the time re -
initiation of study intervention is considered. 
 
7 DISCONTINUATIONS OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1 DISCONTINUATION OF STUDY INTERVENTION  
Refer to the core protocol . 
In addition to the discontinuation criteria described in the core protocol, refer to  Table 7, 
Section  6.6.2, and Section 6.6.3 for toxicities requiring permanent discontinuation of nivolumab 
and/or NKTR -214. 
7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM 
STUDY 
Refer to the core protocol . 
7.[ADDRESS_415621] not be less than 18 days.  
8.1 EFFICACY ASSESSMENTS  
Refer to the core protocol . 
8.1.1 Laboratory Assessments of Clinical Activity  
Samples for the laboratory assessments of clinical activity and hormone levels  in Table 10 will 
be sent to the study site ’s local l aboratory for analysis:  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 49 Table 10:  Laboratory Tests Sent to the Study Site ’s Local Laboratory for Analysis  of 
Disease -related Endpoints  
Profile  Laboratory Test  
Clinical activity  PSA 
Hormone levels  testosterone  
PSA = prostate -speci fic antigen  
 
 
8.2 SAFETY ASSESSMENTS  
Refer to the core protocol  for a description of the assessments for medical history and 
demographic data, physical examinations, vital signs, and electrocardiograms. 
Descriptions of a dditional combination- specific assessmen ts are provided in the following 
sections.  
8.2.1 Increased Monitoring and Vital Sign Guidelines for Infusion -
related Reaction or Hypotension  
If the participant experiences a ≥ Grade 2 infusion- related reaction or hypotension during the 
days after NKTR -214 and/or nivolumab administration, the participant may be monitored 
overnight at the discretion of the Investigator. Longer periods of monitoring may be 
implemented at the disc retion of the Investigator.  
8.2.[ADDRESS_415622] ECHO will be performed to assess cardiac function and LVEF according to the SOA  
(Section 1.3). In the ev ent of an abnormal ECHO, the Investigator may perform a stress ECHO 
(either exercise or nuclear). A MUGA scan can be performed to assess cardiac function and LVEF if a standard echocardiogram cannot be performed. The same assessment method should be used f or the same participant throughout the study.  
8.2.3 Clinical Safety Laboratory Assessments  
[IP_ADDRESS]  Local Laboratory Assessments 
Samples for the laboratory test s in Table 11 will be sent to the study site ’s local laboratory for 
analysis:  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 50 Table 11:  Laboratory Tests Sent to the Study Site ’s Local Laboratory for Analysis  of 
Safety  
Profile  Laboratory Test  
Hematology RBC count  
hemoglobin  
hematocrit 
WBC count with automated differential (neutrophils, eosinophils, basophils, 
monocytes, lymphocytes, other cells)  
platelet count  
manual differential, if clinically indicated  
Clinical Chemistry  
(Serum or Plasma)  sodium  
potassium  
chloride  
bicarbonate glucose  
BUN or urea  
creatinine  
total protein  
albumin calcium  
total bilirubin  
alkaline phosphatase  
ALT  
AST  
LDH  
TSH (T3 and FT 4 should be checked if TSH is outside the normal range)  
coagulation assessments (PT, PTT, INR)
a 
Urinalysis   
ALT = alanine  aminotransferase ; AST = aspartate aminotransferase;  BUN = blood urea nitrogen; 
INR = international normalized ratio ; LDH = lactate d ehydrogenase; PT  = prothrombin time ; PTT = partial 
thromboplastin time ; RBC = red blood cell; TSH = thyroid stimulating hormone; WBC = white blood cell 
a Coagulation assessment not required during treatment phase unless indicated  
 
 
8.[ADDRESS_415623]/Independent Ethics Committee ( IRB/IEC ), as appropriate. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.[ADDRESS_415624] for this immunotherapy combination.  
8.4 TREATMENT OF OVERDOSE 
Refer to the core protocol . 
8.5 PHARMACOKINETICS  
Sparse PK blood sampling will be collected according to the SOA to assess the PK of NKTR -214 and /or nivolum ab. 
PK profiles for NKTR -214 and/or nivolumab may  be performed using a validated assay method 
under the supervision of the Sponsor’s designee.  
8.6 ANTI -DRUG ANTIBODIES  
Immunogenicity  samples will be collected according to the SOA to enable evaluation of anti -
drug antibodies (ADA) to either NKTR -214 and/or nivolumab. Additionally, blood samples 
should also be collected at the final visit from participants who discontinued study intervention or were withdrawn from the study. These samples may  be tested by [CONTACT_37925]'s designee.  
The detecti on and characterization of antibodies to NKTR -214 and/or nivolumab may  be 
performed using a validated assay method under the supervision of the Sponsor’s designee . 
8.7 BIOMARKERS  
Refer to the core protocol . 
8.8 MEDICAL RESOURCE UTILIZAT ION AND HEALTH 
ECONOMICS  
Refer to the core protocol . 
9 STATISTICAL CONSIDERATIONS  
Refer to the core protocol . 
9.5.1  Interim Safety Monitoring  
Refer to the core protocol  for details related to the Safety Assessment Committee (SAC) , the 
committee charged with safety review for this study.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 52 10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
Refer to the core protocol  for the following appendices:  
Appendix 1: Regulatory, Ethical and Study Oversight Considerations  
Appendix 2: Eastern Cooperative Oncology Group (ECOG) Performance Status  
Appendix 3: RECIST Criteria (Version 1.1) with Modifications as Recommended by 
[CONTACT_43877]3  
Appendix 4: Clinical Laboratory Tests  
Appendix 5: Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting 
Appendix 6: Contraceptive Guidance and Collection of Pregnancy Information 
Appendix 7: Genetics  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 53 10.1 APPENDIX A-1 : MANAGEMENT ALGORITHMS  
Management algorithms have been developed to provide guidance for Investigators in assessing 
and managing immune -mediated events  in participants receiving nivolumab . Section 6.6.2 
describes the criteria for dose delay and discontinuation to be followed for nivolumab in this 
cohort . These algorithms are in tended to provide clini cal recommendations. In cases in which the 
modification criteria in  Section 6.6.2 and the algorithms differ, the criteria  in Section 6.6.2 
should take preceden ce. 
The management algorithms are provided for the following groups of drug- related AEs:  
• Immune -mediated gastrointestinal adverse events (diarrhea, colitis)  
• Immune -mediated renal adverse events ( nephritis and renal dysfunction)  
• Immune -media ted pulmonary adverse  events  (pneumonitis ) 
• Immune -mediated hepatic adverse events (hepatitis)  
• Immune -mediated endocrinopath y adverse events  (hypophysitis, adrenal insufficiency, 
hypothyroidism and hyperthyroidism, Type 1 diabetes mellitus)  
• Immune -mediated skin adverse events  
• Immune -mediated neurologic adverse events ( encephalitis ) 
 
 
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.054
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.055
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.056
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.057
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.058
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.059
PORTER Appendix Cohort A - Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033, Version 2.060
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 61 10.2 APPENDIX A-2 : LISTS OF TERMINOLOGY AND 
ABBREVIATIONS  
10.2.[ADDRESS_415625] of Terminology  
Terminology Description  
Cohort  A group of partici pants receiving the same immunotherapy 
combination . 
Cohort appendix  A document that guides the treatment of participants in a given 
cohort. The cohort appendices are identified using a letter 
designation (eg, Appendix Cohort A).  
Core protocol  The master  document that provides the elements common 
across the study and among all cohorts, unless otherwise 
specified . 
Immunotherapy combination  Two or more study interventions administered to a coho rt of 
participants . 
 
10.2.[ADDRESS_415626]-line 
2L second -line 
ACTH  adrenocorticotropic hormone  
ADA  anti-drug antibod y(ies) 
ADP  adenosine diphosphate  
AE(s)  adverse event(s)  
AIDS  acquired immunodeficiency syndrome  
ALT  alanine aminotransferase  
aPTT  activated partial thromboplas tin time  
AST  aspartate aminotransferase  
AUC  area under the concentration -time curve  
BUN  blood urea nitrogen  
C cycle  
Cavgss  average steady -state concentration  
cfDNA  cell-free deoxyribonucleic acid  
cHL classical Hodgkin lymphoma  
Cmax  maximum observed  drug concentration  
Cmaxss  maximum steady -state plasma concentration  
Cminss  minimum steady -state plasma concentration  
Cmin1  trough concentration after the first dose  
CNS  central nervous system  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 62 Abbreviation  Defini tion 
CR complete response  
CRC  colorectal cancer  
CTCAE  Common Terminology Criteria for Adverse Events  
CTLA -4 cytotoxic T -lymphocyte -associated protein 4  
DCR  disease control rate  
DLT  dose limiting toxicity  
dMMR  mismatch repair deficient  
ECG  electrocardiogram  
ECHO  echocardiogram  
ECOG  Eastern Cooperative Oncology  Group  
EOT  end of treatment  
EPO  erythropoietin  
FDA  Food and Drug Administration  
FFPE  formalin -fixed paraffin -embedded  
GCP  Good Clinical Practice  
GFR  glomerular filtration rate  
GnRH  gonadotropin -releasing hormone  
HCC  hepatocellular carcinoma  
HIV human immunodeficiency virus  
I/E inclusion/exclusion  
IB Investigator’s Brochure  
ICF informed consent form  
IgG4  immunoglobulin G4  
IL-2 interleukin 2  
IL-2Rαβγ  IL-2 receptor alpha beta gamma  
IL-2Rβγ  IL-2 receptor beta gamma  
imAE(s)  immune -mediated AE(s)  
INR international normalized ratio  
irAE(s)  immune -related AE(s)  
IRB/IEC  Institutional Review Board/Independent Ethics Committee  
IV intravenous(ly)  
LDH  lactate dehydrogenase  
LVEF left ventricular ejection fraction  
mAb monoclonal antibody  
mCRPC  meta static castration -resistant prostate cancer  
MDSC (s) myeloid -derived suppressor cell (s) 
MedDRA  Medical Dictionary for Regulatory Activities  
MSI-H microsatellite instability -high 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 63 Abbreviation  Defini tion 
MTD  maximum tolerated dose  
MUGA  multigated acquisition  
NCI National Cance r Institute  
NK natural killer  
NKTR -214-AC NKTR -214 active cytokines  
NKTR -214-RC NKTR -214 related cytokines  
NSAIDs  nonsteroidal anti -inflammatory drugs  
NSCLC  non–small -cell lung cancer  
NYHA  [LOCATION_001] Heart Association  
ORR  objective response rate  
OS overall survival  
PARP  poly ADP ribose polyme rase 
PCWG3  Prostate Cancer Clinical Trials Working Group 3  
PD progressive disease  
PD-1 programmed cell death 1  
PD-L1 programed cell death ligand 1  
PEG  polyethylene glycol  
PI [INVESTIGATOR_336385] -specific antigen  
PT prothrombin time  
PTT partial thromboplastin time  
Q2W  every 2 weeks  
Q3M  every  3 months  
Q3W  every 3 weeks  
Q4W  every 4 weeks  
QTcF  Fridericia’s corrected QT interval  
RBC  red blood cell  
RCC  renal cell carcinoma  
RECIST  Response Evaluation Criteria in Solid Tumors  
rhIL-2 recombinant human interleukin -2 
rPFS  radiographic progressi on-free survival  
S screening  
SAC  Safety Assessment Committee  
SAE(s)  serious adverse event(s)  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.[ADDRESS_415627] cancer  
TRAE(s)  treatment -related adverse eve nt(s) 
Treg (s) regulatory tumor cell (s) 
TSH  thyroid stimulating hormone  
UC urothelial carcinoma  
ULN  upper limit of normal  
US [LOCATION_002]  
USPI  [INVESTIGATOR_336386] A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 65 10.3 APPENDIX A-3 : APPENDIX COHORT  A AMENDMENT 
HISTORY  
 
DOCUMENT HISTORY 
Documents  Date of Issue  
Amendment 1 24 Jan 2019  
Original Appendix Cohort A  07 Dec 2018  
 
  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 66 11 REFERENCES  
Addendum 1 to NKTR -214 Investigator’s Brochure version 5.0, dated 03- Jul-2018. Nektar 
Therapeutics, 29- Aug-2018. 
Alexandrov LB, Nik- Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. 
Signatures of mutational processes in human cancer. Nature 2013;500(7463):415–21.  
Boyman O, Sprent J. The role of interleukin- 2 during homeostasis and activation of the i mmune 
system. Nat Rev Immunol 2012;12(3):180–90.  Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, et al. NKTR -214, an 
engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked 
efficacy in mouse tumor models . Clin Cancer Res 2016a;22(3):680–90.  
Charych DH, Rubas W, Dixit V, Cetz  J, Pena R, Langowski JL, et al. Immune memory in 
nonclinical models after treatment with NKTR -214, an engineered cytokine biased towards 
expansion of CD8+ T cells in tumor. Presented  at: American Society of Clinical Oncology 2016 
Annual Meeting ; June  3-7, 2016; Chicago, IL . J Clin Oncol 2016b;34(15_suppl ; abstract [ZIP_CODE]) . 
Available at:  https://meetinglibrary.asco.org/record/126793/abstract. Accessed on 18- Oct-2018.  
Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR -214, a kinetically -controlled 
interleukin -2 (IL2) receptor agonist for cancer immunotherapy. PLoS ONE 
2017;12(7):e0179431.  
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256–69.  
Diab A, Tannir NM, Bernatchez C, Haymaker CL, Bentebibel SE, Curti BD, et al. A phase 1/[ADDRESS_415628] locally 
advan ced or metastatic solid tumors. Presented at: American Society of Clinical Oncology 2017 
Annual Meeting; June 2- 6. 2017; Chicago, IL. J Clin Oncol 2017a;35(15_suppl ; abstract 
e14040).  Available at: https://meetinglibrary.asco.org/record/149613/abstract . Accessed on 
18-Oct-2018.  
Diab A, Tannir N, Cho D, Papadimitrakopoulou V, Bernatchez C, Haymaker C, et al. Pi[INVESTIGATOR_53643] -02: 
Preliminary safety, efficacy and biomarker results from dose escalation of the Phase 1/[ADDRESS_415629] NKTR -214 plus nivolumab in patients with locally advanced/metastatic 
melanoma, renal cell carcinoma and non -small cell lung cancer. Presented at: Society for 
Immunotherapy of Cancer 2017; November 8 -12, 2017b; National Harbor, MD. Available at: 
http://www.nektar.com/application/files/8115/1042/7902/SITC2017_- Oral_Session_207_-
_PI[INVESTIGATOR_12964] -02_-_Adi_Diab -preso.pdf. Accessed on 22- Mar-2018.  
Diab A, Hurwitz M, Cho D, Papadimitrakopoulou V, Curti B , Tykodi S , et al. N KTR -214 
(CD-122-biased agonist)  plus nivolumab in patients with advanced solid tumors: Preliminary  
phase 1/2 results of PI[INVESTIGATOR_12964] . Presented at: American Society of Clinical Oncology ; June 1- 5, 
2018; Chi cago, IL . Available at: 
https://www.nektar.com/applicatio n/files/1815/2797/2670/NKTR -
214_Oral_Presentation_ASCO_02Jun2018- Final. pdf. Accessed on 04- Oct-2018. 
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.[ADDRESS_415630] R, et al. New response 
evaluation criteria in solid tumours: revised RECIST guideline ( version 1.1). Eur J Cancer 
2009;45(2):228–47.  
Flammiger  A, Bayer F, Cirugeda -Kühnert A, Huland H, Tennstedt P, Simon R, et al. 
Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer. APMIS 
2012;120(11):901–8.  
Graff JN, Al umkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, et al. Early evidence of 
anti-PD-1 activity in enzalutamide -resistant prostate cancer. Oncotarget 2016;7(33):[ZIP_CODE]–7.  
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipi[INVESTIGATOR_336387] m etastatic castration -resistant prostate cancer 
that had progressed after docetaxel chemotherapy (CA184 -043): a multicentre, randomised, 
double -blind, phase 3 trial. Lancet Oncol 2014;15(7):700–12.  
Lopez-Bujanda Z, Drake CG. Myeloid- derived cells in prosta te cancer progression: phenotype 
and prospective therapi[INVESTIGATOR_014]. J Leukoc Biol 2017;102(2):393–406.  
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of 
PD-L1 expre ssion in prostate cancer: Innate and adaptive immune res istance. Prostate Cancer 
Prostatic Dis 2015;18(4):325–32.  
Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD -1, PD -
L1 and T lymphocyte expression on tissue from cas tration -resistant prostate adenocarcinoma: An 
explorator y analysis. Target Oncol 2016;11(3):345–51.  
McDermott DF, Cheng S -C, Signoretti S, Margolin KA, Clark JI, Sosman JA, et al. The high-
dose aldesleukin “select” trial: A trial to prospectively validate  predictive models of response to 
treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015;21(3):561–8.  Miller AM, Lundberg K, Ozenci V, Banham AH, Hellström M, Egevad L, et al. CD4+CD25high 
T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177(10):7398–405.  
Nivolumab Investigator ’s Brochure version 17, dated 27- Jun-2018. Bristol -Myers Squibb 
Research and Development, 2018. Document Control No. 930038243. NKTR -214 Investigator’s Broc hure version 5.0, dated 03- Jul-2018. Nektar Therapeutics , 2018. 
Opdivo (nivolumab) US Prescribing Information (USPI), Nov -2018; Bristol -Myers Squibb 
Company, Princeton, NJ. Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin- Pi[INVESTIGATOR_48820] J, Rocchi  P, et al. Inhe rent and 
tumor -driven immune tolerance in the prostate microenvironment impairs natural killer cell 
antitumor activity. Cancer Res 2016;76(8):2153–65.  Payne R, Glenn L, Hoen H, Richards B, Smith JW, Lufkin R, et al. Durable responses and 
reversible toxicity of high- dose interleukin- 2 treatment of melanoma and renal cancer in a 
Community Hospi[INVESTIGATOR_336388]. J Immunother Cancer 2014;2:13.  
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and 
objectives  for castration -resistant prostate cancer: Updated recommendations from the Prostate 
Cancer Clinical Trials Working Group 3. J Clin Oncol 2016;34(12):1402–18.  
PORTER Appendix Cohort A -  Parker Institute for Cancer Immunotherapy  
Protocol PI[CONTACT_150876]0033 Appendix Amendment 1, Version 2.0 68 Sfanos KS, Bruno TC, Meeker AK, De Marzo AM, Isaacs WB, Drake CG. Human prostate -
infiltrating CD 8+ T lymphocyte s are oligoclonal and PD -1+. Prostate 2009;69(15):1694–703.  
Study 1 5-214-01 (EXCEL; [STUDY_ID_REMOVED]): A Phase 1/2 Multicenter Dose Escalation and 
Expansion Study of NKTR -214 i n Subjects  with Locally  Advanced or  Metastatic Solid Tumors  
(NKTR -214). ClinicalTria ls.gov. Available at: https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. 
Accessed on 09- Oct-2018. 
Study 16 -214-02 (PI[INVESTIGATOR_12964] -02; [STUDY_ID_REMOVED]): A Dose Escalation and Cohort Expansion Study 
of CD122- Biased Cytokine (NKTR -214) in Combination w ith Ant i-PD-1 Antibody  (Nivolumab) 
in Patients w ith Select Advanced or Metastatic Solid Tumors. ClinicalTrials.gov. Available at: 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]. Accessed on 09- Oct-2018. 
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, M cDermott DF, et  al. Safety, 
activity, and immune correlates of anti -PD-1 antibody in cancer. N Engl J Med 
2012;366(26):2443–54. 